Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis by Hobbs, BD et al.
 
 
1 
Data Supplement for: 
 
Twenty-two genetic loci in COPD overlap with population-based lung function and pulmonary 
fibrosis 
 
Brian D. Hobbs1,2, Kim de Jong3,4, Maxime Lamontagne5, Yohan Bossé5, Nick Shrine6, María Soler 
Artigas6, Louise V. Wain6, Ian P. Hall7, Victoria E. Jackson6,8, Annah B. Wyss9, Stephanie J. London10, 
Kari E. North11, Nora Franceschini11, David P. Strachan12, Terri H. Beaty13, John E. Hokanson14, James 
D. Crapo15,57, Peter J. Castaldi1,16, Robert P. Chase1, Traci M. Bartz17,18, Susan R. Heckbert17,19,20, Bruce 
M. Psaty17,21,20, Sina A. Gharib22, Pieter Zanen23, Jan W. Lammers24, Matthijs Oudkerk25, H. J. Groen26, 
Nick Locantore27, Ruth Tal-Singer27, Stephen I. Rennard28,29, Wim Timens30, Peter D. Paré31, Jeanne 
C. Latourelle32, Josée Dupuis33,34, George T. O'Connor34,35, Jemma B. Wilk34, Woo Jin Kim36, Mi Kyeong 
Lee36, Yeon-Mok Oh37, Judith M. Vonk3,4, Harry J. de Koning38, Shuguang Leng39, Steven A. Belinsky39, 
Yohannes Tesfaigzi39, Ani Manichaikul40,41, Xin-Qun Wang41, Stephen S. Rich40,41, R Graham Barr42, 
David Sparrow43, Augusto L. Litonjua1,2, Per Bakke44, Amund Gulsvik44, Lies Lahousse45,46, Guy G. 
Brusselle47, Bruno H. Stricker45,48,49,50, André G. Uitterlinden45,49,50, Elizabeth J. Ampleford51, Eugene 
R. Bleecker51, Prescott G. Woodruff52, Deborah A. Meyers51, Dandi Qiao1, David A. Lomas53, Jae-Joon 
Yim54, Deog Kyeom Kim55, Iwona Hawrylkiewicz56, Pawel Sliwinski56, Megan Hardin1,2, Tasha E. 
Fingerlin57,58, David A. Schwartz57,59,60, Dirkje S. Postma26,4, William MacNee61, Martin D. Tobin6,62, 
Edwin K. Silverman1,2, H. Marike Boezen3,4, *Michael H. Cho1,2, COPDGene Investigators, ECLIPSE 
Investigators, LifeLines Investigators, SPIROMICS Research Group, International COPD Genetics 
Network Investigators, UK BiLEVE Investigators, International COPD Genetics Consortium 
 
1 Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA 
2 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, 
USA 
3 University of Groningen, University Medical Center Groningen, Department of Epidemiology, 
Groningen, the Netherlands 
4 University of Groningen, University Medical Center Groningen, Groningen Research Institute for 
Asthma and COPD (GRIAC), Groningen, the Netherlands 
5 Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Canada 
6 Genetic Epidemiology Group, Department of Health Sciences, University of Leicester, Leicester, 
UK 
7 Division of Respiratory Medicine, Queen’s Medical Centre, University of Nottingham, Nottingham, 
UK 
8 Department of Health Sciences, University of Leicester, Leicester, UK 
9 Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle 
Park, NC, USA 
10 Epidemiology Branch, National Institute of Environmental Health Sciences, National Institutes of 
Health, Department of Health and Human Services, Research Triangle Park, NC, USA 
11 Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA 
12 St George's, University of London, Cranmer Terrace, London SW17 0RE, UK 
13 Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA 
14 Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA 
15 National Jewish Health, Denver, CO, USA 
16 Division of General Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA 
17 Cardiovascular Health Research Unit, University of Washington, Seattle, WA, USA 
18 Departments of Medicine and Biostatistics, University of Washington, Seattle, WA, USA 
19 Department of Epidemiology, University of Washington, Seattle, WA, USA 
20 Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA 
 
 
2 
21 Departments of Epidemiology, Medicine and Health Services, University of Washington, Seattle, 
WA, USA 
22 Computational Medicine Core, Center for Lung Biology, UW Medicine Sleep Center, Department 
of Medicine, University of Washington, Seattle, WA, USA 
23 University Medical Center Utrecht, Department of Pulmonary Diseases, Utrecht, the Netherlands 
24 Department of Pulmonology, University Medical Center Utrecht, University of Utrecht, Utrecht, 
the Netherlands 
25 Department of Radiology, University Medical Center Groningen, University of Groningen, 
Groningen, the Netherlands 
26 University of Groningen, University Medical Center Groningen, Department of Pulmonology, 
Groningen, the Netherlands 
27 GSK R&D, King of Prussia, PA, USA 
28 Pulmonary, Critical Care, Sleep and Allergy Division, Department of Internal Medicine, 
University of Nebraska Medical Center, Omaha, NE, USA 
29 Clincal Discovery Unit, AstraZeneca, Cambridge, UK 
30 Department of Pathology and Medical Biology, University of Groningen, University Medical 
Center Groningen, GRIAC Research Institute, Groningen, the Netherlands 
31 University of British Columbia Center for Heart Lung Innovation and Institute for Heart and 
Lung Health, St Paul’s Hospital, Vancouver, British Columbia, Canada 
32 Department of Neurology, Boston University School of Medicine, Boston, MA, USA 
33 Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA 
34 The National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, MA, USA 
35 Pulmonary Center, Department of Medicine, Boston University School of Medicine, Boston, MA, 
USA 
36 Department of Internal Medicine and Environmental Health Center, School of Medicine, 
Kangwon National University, Chuncheon, South Korea 
37 Department of Pulmonary and Critical Care Medicine, and Clinical Research Center for Chronic 
Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 
South Korea 
38 Department of Public Health, Erasmus Medical Center Rotterdam, Rotterdam, the Netherlands 
39 Lovelace Respiratory Research Institute, Albuquerque, NM, USA 
40 Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA 
41 Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA 
42 Department of Medicine, College of Physicians and Surgeons and Department of Epidemiology, 
Mailman School of Public Health, Columbia University, New York, NY, USA 
43 VA Boston Healthcare System and Department of Medicine, Boston University School of 
Medicine, Boston, MA, USA 
44 Department of Clinical Science, University of Bergen, Bergen, Norway 
45 Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands 
46 Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium 
47 Department of Public Health, Erasmus Medical Center, Rotterdam, the Netherlands 
48 Netherlands Health Care Inspectorate, The Hague, the Netherlands 
49 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands 
50 Netherlands Genomics Initiative (NGI)-sponsored Netherlands Consortium for Healthy Aging 
(NCHA), Leiden, the Netherlands 
51 Center for Genomics and Personalized Medicine Research, Wake Forest University School of 
Medicine, Winston Salem, NC, USA 
52 Cardiovascular Research Institute and the Department of Medicine, Division of Pulmonary, 
Critical Care, Sleep, and Allergy, University of California at San Francisco, San Francisco, CA, USA 
53 University College London, London, UK 
 
 
3 
54 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul 
National University College of Medicine, South Korea 
55 Seoul National University College of Medicine, SMG-SNU Boramae Medical Center, Seoul, South 
Korea 
56 National Tuberculosis and Lung Disease Research Institute, Warsaw, Poland 
57 Center for Genes, Environment and Health, National Jewish Health, Denver, CO, USA 
58 Department of Biostatistics and Informatics, University of Colorado 
Denver, Aurora, CO, USA 
59 Department of Medicine, School of Medicine, University of Colorado Denver, Aurora, CO, USA 
60 Department of Immunology, School of Medicine, University of Colorado Denver, Aurora, CO, USA 
61 University of Edinburgh, Edinburgh, UK 
62 National Institute for Health Research (NIHR) Leicester Respiratory Biomedical Research Unit, 
Glenfield Hospital, Leicester, UK 
 
 
*Corresponding author: 
Michael H. Cho (remhc@channing.harvard.edu) 
tel: 617-525-0897 
fax: 888-487-1078 
 
  
 
 
4 
Supplemental Figures: 
Figures S1a-v: Forest plots illustrate the association results at the individual cohort level in each 
stage of the analysis for each of the 22 genome-wide significant loci. For the Stage 1 analysis portion 
of the forest plots, the studies are grouped into studies containing individuals of European ancestry 
and studies containing individuals of non-European ancestry. The “Stage 1” odds ratio (OR) and 
95% confidence interval (CI) represents a meta-analysis across the 26 Stage 1 analysis studies. The 
“Stage 2: BiLEVE” OR represents the meta-analysis of UK BiLEVE never smokers and heavy 
smokers. The “Overall” OR represents the cumulative meta-analysis across the Stage 1 results and 
the UK BiLEVE Stage 2 results. If the marker was not available in a specific cohort, the cohort is 
missing from the forest plot. Study abbreviations: ARIC = Atherosclerosis Risk in Communities, B58 = 
British 1958 Birth Cohort, CHS = Cardiovascular Health Study, COPACETIC = COPD Pathology: Addressing 
Critical gaps, Early Treatment & Diagnosis and Innovative Concepts, ECLIPSE = Evaluation of COPD 
Longitudinally to Identify Predictive Surrogate End-points, eQTL = Lung Expression Quantitative Trait Loci 
Study, FHS = Framingham Heart Study, KARE = Korean Association Resource project, MESA = Multi-Ethnic 
Study of Atherosclerosis, NETT-NAS = National Emphysema Treatment Trial / Normative Aging Study, RS = 
Rotterdam Study, SPIROMICS = Subpopulations and intermediate outcome measures in COPD study , EOCOPD 
= Boston Early-Onset COPD Study, ICGN = International COPD Genetics Network, TCGS = Transcontinental 
COPD Genetics Study, BiLEVE = UK Biobank Lung Exome Variant Evaluation; NHW = Non-Hispanic white, AA 
= African American, EA = European American. 
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Figure S1a: Forest plot for rs13141641 (HHIP) 
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Figure S1b: Forest plot for rs17486278 (CHRNA5) 
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Figure S1c: Forest plot for rs7733088 (HTR4) 
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Figure S1d: Forest plot for rs9399401 (ADGRG6) 
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Figure S1e: Forest plot for rs1441358 (THSD4) 
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Figure S1f: Forest plot for rs6837671 (FAM13A) 
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Figure S1g: Forest plot for rs11727735 (GSTCD) 
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Figure S1h: Forest plot for rs754388 (RIN3) 
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Figure S1i: Forest plot for rs113897301 (ADAM19) 
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Figure S1j: Forest plot for rs2047409 (TET2) 
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Figure S1k: Forest plot for rs2955083 (EEFSEC) 
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Figure S1l: Forest plot for rs7186831 (CFDP1) 
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Figure S1m: Forest plot for rs10429950 (TGFB2) 
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Figure S1n: Forest plot for rs2070600 (AGER) 
 
 
 
  
Overall
0.02 0.14 1.00 7.39 54.60 403.43
Odds Ratio
bileve−smoker
bileve−neverSmoker
TCGS−Korea
TCGS−Poland
SPIROMICS
RS3
RS2
RS1
Norway/GenKOLS
NETT−NAS
LifeLines
FHS
EQTL
EOCOPD,ICGN
ECLIPSE
COPDGene NHW
COPACETIC
CHS EA
ARIC
 1.31 [ 1.16 ,   1.49 ]
 1.11 [ 0.98 ,   1.26 ]
 1.32 [ 0.69 ,   2.49 ]
 0.85 [ 0.29 ,   2.47 ]
 1.45 [ 0.83 ,   2.56 ]
14.51 [ 0.72 , 290.61 ]
 0.79 [ 0.05 ,  11.37 ]
 3.74 [ 0.27 ,  50.77 ]
 0.91 [ 0.61 ,   1.35 ]
 1.46 [ 0.91 ,   2.33 ]
 1.48 [ 0.95 ,   2.31 ]
 1.17 [ 0.82 ,   1.67 ]
 1.07 [ 0.52 ,   2.19 ]
 1.16 [ 0.82 ,   1.66 ]
 1.52 [ 0.82 ,   2.80 ]
 1.43 [ 1.16 ,   1.77 ]
 1.50 [ 0.93 ,   2.42 ]
 1.07 [ 0.77 ,   1.49 ]
 1.26 [ 0.97 ,   1.63 ]
 1.24 [ 1.16 ,   1.32 ]
6:32151443  rs2070600
1.27 [ 1.15 , 1.42 ]Europeans
1.32 [ 0.69 , 2.49 ]non−Europeans
1.28 [ 1.15 , 1.41 ]Stage 1
1.21 [ 1.11 , 1.32 ]Stage 2: BiLEVE
 
 
19 
Figure S1o: Forest plot for rs17707300 (CCDC101) 
 
 
  
Overall
0.37 0.61 1.00 1.65 2.72
Odds Ratio
bileve−smoker
bileve−neverSmoker
TCGS−Korea
MESA Hispanic
MESA AA
KARE
COPDGene AA
CHS AA
TCGS−Poland
SPIROMICS
RS3
RS2
RS1
Norway/GenKOLS
NETT−NAS
MESA Caucasian
Lovelace
LifeLines
FHS
EQTL
EOCOPD,ICGN
ECLIPSE
COPDGene NHW
COPACETIC
CHS EA
B58
ARIC
1.09 [ 1.02 , 1.15 ]
1.04 [ 0.98 , 1.11 ]
1.18 [ 0.53 , 2.63 ]
1.44 [ 0.88 , 2.33 ]
1.08 [ 0.71 , 1.63 ]
1.30 [ 0.97 , 1.75 ]
1.08 [ 0.91 , 1.28 ]
1.26 [ 0.86 , 1.86 ]
1.42 [ 1.10 , 1.84 ]
1.31 [ 1.00 , 1.72 ]
1.03 [ 0.75 , 1.42 ]
1.26 [ 0.89 , 1.77 ]
1.61 [ 1.19 , 2.18 ]
1.03 [ 0.86 , 1.23 ]
1.18 [ 0.95 , 1.46 ]
0.88 [ 0.67 , 1.15 ]
0.97 [ 0.76 , 1.25 ]
0.93 [ 0.75 , 1.16 ]
1.00 [ 0.87 , 1.16 ]
0.90 [ 0.67 , 1.20 ]
1.21 [ 1.05 , 1.39 ]
1.22 [ 0.93 , 1.59 ]
1.18 [ 1.08 , 1.30 ]
1.25 [ 1.06 , 1.46 ]
1.18 [ 1.02 , 1.37 ]
1.09 [ 0.89 , 1.34 ]
0.99 [ 0.89 , 1.11 ]
1.10 [ 1.06 , 1.13 ]
16:28593347  rs17707300
1.12 [ 1.07 , 1.16 ]Europeans
1.16 [ 1.02 , 1.32 ]non−Europeans
1.12 [ 1.08 , 1.17 ]Stage 1
1.06 [ 1.02 , 1.11 ]Stage 2: BiLEVE
 
 
20 
Figure S1p: Forest plot for rs2806356 (ARMC2) 
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Figure S1q: Forest plot for rs16825267 (PID1) 
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Figure S1r: Forest plot for rs2076295 (DSP) 
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Figure S1s: Forest plot for rs647097 (MTCL1) 
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Figure S1t: Forest plot for rs1529672 (RARB) 
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Figure S1u: Forest plot for rs721917 (STFPD) 
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Figure S1v: Forest plot for rs12459249 (CYP2A6) 
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Figure S2a-v: LocusZoom1 plots for each of the 22 genome-wide significant loci. The point size for 
each SNP is determined by the sample size for the SNP. The most significant variant in each plot as 
well as the largest points in each plot were tested in all available cohorts including UK BiLEVE. 
Smaller points indicate the variant was not tested in UK BiLEVE Stage 2 analysis and thus the -log10 
P value is taken from the Stage 1 analysis. 
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Figure S3a-xxxxx: LocusZoom1 plots for the meta-analysis across the three Stage 1 cohorts of 
African Ancestry, including the Cardiovascular Health Study (CHS) African Americans, COPDGene 
study African American, and the Multi-Ethnic Study of Atherosclerosis (MESA) African Americans. 
The loci shown each had an association signal with P < 0.001 in the meta-analysis across Stage 1 
cohorts of African ancestry. The labeled variant is the top variant at the locus from the overall meta-
analysis and the r2 represents the African ancestry LD pattern relative to the top variant from the 
overall meta-analysis. Point size indicates the sample size for each variant. 
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Figure SXXX: Comparison of effect size (beta) in the sensitivity analysis evaluating pre- and post-
bronchodilator definitions of COPD for each of the 22 genome-wide significant loci. 
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Figure SXXX: Comparison of -log10P values in the sensitivity analysis evaluating pre- and post-
bronchodilator definitions of COPD for each of the 22 genome-wide significant loci. 
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Supplemental Tables: 
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Supplemental Table S1. Cohort baseline characteristics in COPD cases and controls. 
 
Cohort 
N Age % Female % Ever smokers Pack-years FEV1 % predicted 
Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls Cases Controls 
ARIC 1060 6164 56.8 (5.4) 54.2 (5.6) 43.5 55.9 87.6 51.9 37.7 (25.7) 11.9 (17.9) 64.7 (12.5) 99.9 (11) 
B58 205 3665 45 (0.3) 45 (0.3) 53.7 51.2 75 60.4 16.2 (14.2) 8.6 (11.4) 68.1 (9.5) 99.1 (11) 
CHS EA 736 1586 73.1 (5.6) 71.7 (5) 44.6 71.4 72.7 40.2 31.4 (31.2) 10 (18.8) 59.8 (16.1) 100 (13.6) 
COPACETIC 397 1906 61.9 (6.1) 59.7 (5.4) 2 1.6 100 100 45.6 (19.6) 38.9 (17.1) 65.3 (11.8) 106.9 (12.8) 
COPDGene NHW 3068 2110 64.4 (8.3) 59.2 (8.6) 45.9 49.8 100 100 54.9 (27.1) 37.3 (20.1) 48.4 (18.5) 95.7 (10.7) 
ECLIPSE 1741 149 63.6 (7.1) 57.3 (9.5) 33.1 42.8 100 100 50.4 (27.4) 30.9 (25.8) 43.3 (14.8) 105.2 (12.1) 
EOCOPD * 394 495 53.6 (12.5) 40.5 (17.8) 60.2 57.2 88.3 63.3 39.8 (25.3) 10.4 (18.3) 38.4 (22.1) 97.2 (10.8) 
ICGN * 1852 557 59 (7.1) 54.4 (8.9) 42.3 49.5 100 100 50.7 (28.2) 28.8 (20) 42.6 (18.1) 101.8 (13.9) 
EQTL 252 224 64.6 (8.8) 61.5 (10.3) 38.9 50 98.4 86.2 52.6 (29.5) 38.6 (23.4) 61.1 (15.3) 97.7 (11.5) 
FHS 701 5110 62.2 (11.8) 51.9 (13.3) 47.8 55 80.3 48.4 31.5 (27.6) 7.4 (14) 65.6 (11.9) 102.1 (11.9) 
LifeLines 466 9863 53.9 (11.8) 47 (10.7) 48.9 59.9 77.9 54.4 17.2 (16.6) 6.4 (9.5) 70 (9.1) 105.1 (12) 
Lovelace 259 641 64.9 (8.1) 54.4 (9.1) 78.7 81.3 100 100 52.7 (24.3) 36.6 (18.4) 61.5 (14.5) 100.1 (11.8) 
MESA Caucasian 167 754 68.4 (8.9) 64.5 (9.7) 48.5 53.3 79.6 53.1 33.9 (34.2) 12.3 (20.4) 66 (12.4) 99 (11.7) 
NETT-NAS 376 435 67.5 (5.8) 69.8 (7.5) 35.9 0 100 100 66.4 (30.7) 40.7 (27.8) 24.9 (6.6) 100 (13.2) 
Norway/GenKOLS 846 695 65.5 (10.1) 55.4 (9.7) 41.7 50.2 100 100 31.9 (18.6) 19.4 (13.6) 46.4 (17) 92.6 (8.9) 
RS1 112 815 79.5 (5) 78.5 (4.5) 38 60.5 83.9 61.8 28.6 (24.3) 12.3 (18) 64.5 (11.7) 113.4 (18) 
RS2 94 811 73 (6) 71.6 (4.9) 44 55.6 90.4 61.3 33.4 (26.2) 12.1 (18.9) 64.2 (11.8) 108.6 (15.7) 
RS3 106 1596 63 (6) 61.6 (5.4) 49 58.2 90.6 64 37.4 (28.2) 11.1 (16.4) 64.6 (12.7) 108.8 (14.3) 
SPIROMICS 571 175 66.6 (7.6) 64.1 (9.2) 44.1 54 100 100 55.6 (24.2) 43.8 (23.8) 48.4 (18) 95.8 (10.8) 
TCGS-Poland * 307 311 62.6 (7.4) 59.1 (7.2) 31.5 32.6 100 100 44.6 (22.5) 34.1 (15.1) 29.3 (9.6) 102.9 (12.6) 
CHS AA 138 292 72.8 (5.2) 73 (5.3) 53.6 69.9 70.3 48.6 20.6 (25.1) 9.7 (17.1) 60.6 (14.2) 102.5 (14.6) 
COPDGene AA 910 1556 58.6 (8.1) 52.8 (6) 46.8 43.8 100 100 42.7 (23.5) 36.1 (19.1) 51.2 (18.1) 97.2 (11.8) 
KARE 199 6741 60.8 (8.4) 54.8 (8.6) 18 56 72.4 34.4 34.7 (20.1) 25.2 (17.9) 68 (9.5) 113.5 (15.2) 
MESA AA 94 532 67.6 (9) 64.4 (9.4) 33 58.3 78.7 49.4 27.7 (26.7) 9.8 (16.2) 64.1 (13.9) 100.2 (14.5) 
MESA Hispanic 52 548 68.4 (9.3) 63.3 (9.4) 32.7 55.8 71.2 41.8 25.4 (31.8) 6.9 (14.4) 65.1 (13.6) 100.4 (12.4) 
TCGS-Korea * 153 205 68.5 (6.8) 52.8 (8.4) 1.6 3.4 100 100 44.3 (24.5) 27.6 (15) 34.8 (10.2) 95.5 (9.2) 
UK BiLEVE Never Smokers 3737 4871 58.3 (7.7) 56.9 (7.9) 47.6 49.9 0 0 0 0 65.4 (11.4) 130.3 (8.3) 
UK BiLEVE Heavy Smokers 5761 4877 59.3 (6.9) 56.9 (7.9) 45.5 49.8 100 100 41.6 (20.9) 29.8 (13.9) 61.2 (11.8) 118 (8.1) 
Shaded studies have participants of European ancestry. All values represented as N, %, or mean (sd). ARIC = Atherosclerosis Risk in Communities, B58 = 
British 1958 Birth Cohort, CHS = Cardiovascular Health Study, COPACETIC = COPD Pathology: Addressing Critical gaps, Early Treatment & Diagnosis 
and Innovative Concepts, ECLIPSE = Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points, eQTL = Lung Expression 
Quantitative Trait Loci Study, FHS = Framingham Heart Study, KARE = Korean Association Resource project, MESA = Multi-Ethnic Study of 
Atherosclerosis, NETT-NAS = National Emphysema Treatment Trial / Normative Aging Study, RS = Rotterdam Study, SPIROMICS = Subpopulations and 
intermediate outcome measures in COPD study , EOCOPD = Boston Early-Onset COPD Study, ICGN = International COPD Genetics Network, TCGS = 
Transcontinental COPD Genetics Study, UK BiLEVE = UK Biobank Lung Exome Variant Evaluation; NHW = Non-Hispanic white, AA = African American, 
EA = European American. * Indicates the four studies with custom genotyping content (i.e. they did not have genome-wide data)
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Supplemental Table S2. Ancestry and genomic control factor for each cohort in the Stage 1 meta-
analysis. 
Cohort Ancestry 
Effective 
Sample Size 
Genomic 
Control Factor 
ARIC European 3617.9 1.026 
B58 European 776.6 1.009 
CHS EA European 2010.8 1.016 
COPACETIC European 1314.3 1.013 
COPDGene NHW European 5000.8 1.017 
ECLIPSE European 549 1 
EOCOPD, ICGN * European 2590.4 NA 
EQTL European 474.4 1.003 
FHS European 2465.7 1.035 
LifeLines European 1779.9 1.019 
Lovelace European 737.9 1.032 
MESA Caucasian European 546.9 1.03 
NETT-NAS European 806.7 1.038 
Norway/GenKOLS European 1526.2 1.009 
RS1 European 393.9 1.025 
RS2 European 336.9 1.036 
RS3 European 397.6 1.012 
SPIROMICS European 535.8 1.017 
TCGS-Poland * European 618 NA 
CHS AA African American 374.8 1.044 
COPDGene AA African American 2296.8 1.009 
KARE Korean 773.2 1 
MESA AA African American 319.5 1.026 
MESA Hispanic Hispanic 190 1.006 
TCGS-Korea * Korean 350.4 NA 
* These studies did not have genome-wide data available for analysis. 
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Supplemental Table S3. Full results table for all 79 variants submitted for testing in UK BiLEVE 
Stage 2 analysis. The top 22 variants with overall meta-analysis P value < 5x10-8 are shaded. 
Supplemental Table S3 is attached in Excel format “icgcSuppTableS3_fullStage2Testing.xlsx”. 
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Supplemental Table S4. Association of top 22 loci from meta-analysis of Stage 1 cohorts of European ancestry. 
rsID Closest Gene Locus 
Risk 
Allele 
Alt 
Allele 
Average Risk Allele 
Freq (Range) 
Stage 1 
OR (95% CI) 
Stage 1 
P Value 
rs13141641 HHIP 4q31.21 T C 0.594 (0.524-0.627) 1.229 (1.178-1.281) 4.05E-22 
rs17486278 CHRNA5 15q25.1 C A 0.358 (0.305-0.442) 1.231 (1.181-1.284) 3.04E-22 
rs7733088 HTR4 5q32 G A 0.602 (0.575-0.633) 1.193 (1.139-1.25) 8.30E-14 
rs9399401 ADGRG6 6q24.1 T C 0.724 (0.707-0.748) 1.124 (1.073-1.177) 6.13E-07 
rs1441358 THSD4 15q23 G T 0.333 (0.316-0.349) 1.106 (1.06-1.153) 3.30E-06 
rs6837671 FAM13A 4q22.1 G A 0.406 (0.364-0.454) 1.156 (1.11-1.204) 2.19E-12 
rs11727735 GSTCD 4q24 A G 0.936 (0.926-0.949) 1.271 (1.169-1.383) 2.14E-08 
rs754388 RIN3 14q32.12 C G 0.824 (0.812-0.851) 1.213 (1.148-1.281) 5.39E-12 
rs113897301 ADAM19 5q33.3 AT A 0.175 (0.15-0.187) 1.213 (1.154-1.271) 1.09E-10 
rs2047409 TET2 4q24 A G 0.617 (0.585-0.649) 1.112 (1.065-1.162) 1.45E-06 
rs2955083 EEFSEC 3q21.3 A T 0.881 (0.854-0.893) 1.197 (1.119-1.28) 1.58E-07 
rs7186831 CFDP1 16q23.1 A G 0.434 (0.417-0.452) 1.122 (1.063-1.185) 2.82E-05 
rs10429950 TGFB2 1q41 T C 0.733 (0.698-0.773) 1.138 (1.087-1.191) 4.14E-08 
rs2070600 AGER 6p21.32 C T 0.957 (0.945-0.987) 1.275 (1.149-1.415) 5.10E-06 
rs17707300 CCDC101 16p11.2 C T 0.374 (0.338-0.433) 1.119 (1.073-1.167) 1.19E-07 
rs2806356 ARMC2 6q21 C T 0.185 (0.158-0.198) 1.122 (1.065-1.181) 1.17E-05 
rs16825267 PID1 2q36.3 C G 0.929 (0.92-0.942) 1.294 (1.186-1.412) 7.19E-09 
rs2076295 DSP 6p24.3 T G 0.543 (0.442-0.581) 1.121 (1.077-1.166) 1.78E-08 
rs647097 MTCL1 18p11.22 C T 0.269 (0.259-0.297) 1.096 (1.046-1.148) 1.23E-04 
rs1529672 RARB 3p24.2 C A 0.834 (0.821-0.862) 1.181 (1.119-1.247) 1.80E-09 
rs721917 SFTPD 10q22.3 G A 0.425 (0.403-0.458) 1.083 (1.041-1.127) 8.85E-05 
rs12459249 CYP2A6 19q13.2 C T 0.664 (0.617-0.702) 1.124 (1.064-1.186) 2.81E-05 
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Supplemental Table S5. Association of top 22 loci from meta-analysis across the three Stage 1 cohorts of African ancestry. 
 
rsID 
Closest 
Gene Locus 
Risk 
Allele 
Alt 
Allele 
Average Risk 
Allele Freq 
Stage 1 
OR (95% CI) 
Stage 1 
P Value 
rs13141641 HHIP 4q31.21 T C 0.88 1.22 (1.01 - 1.47) 0.042 
rs17486278 CHRNA5 15q25.1 C A 0.29 1.22 (1.07 - 1.39) 2.2E-03 
rs7733088 HTR4 5q32 G A 0.67 1.03 (0.916 - 1.17) 0.59 
rs9399401 ADGRG6 6q24.1 T C 0.62 1.19 (1.05 - 1.34) 5.3E-03 
rs1441358 THSD4 15q23 G T 0.53 1.26 (1.13 - 1.42) 5.1E-05 
rs6837671 FAM13A 4q22.1 G A 0.58 1.11 (0.989 - 1.25) 0.075 
rs11727735 GSTCD 4q24 A G --- --- --- 
rs754388 RIN3 14q32.12 C G 0.86 1.2 (1.01 - 1.42) 0.036 
rs113897301 ADAM19 5q33.3 AT A 0.05 0.852 (0.645 - 1.13) 0.26 
rs2047409 TET2 4q24 A G 0.32 1.07 (0.944 - 1.2) 0.30 
rs2955083 EEFSEC 3q21.3 A T 0.88 1.15 (0.955 - 1.38) 0.14 
rs7186831 CFDP1 16q23.1 A G 0.23 1.15 (0.981 - 1.34) 0.086 
rs10429950 TGFB2 1q41 T C 0.64 1.07 (0.953 - 1.21) 0.25 
rs2070600 AGER 6p21.32 C T --- --- --- 
rs17707300 CCDC101 16p11.2 C T 0.16 1.1 (0.952 - 1.28) 0.19 
rs2806356 ARMC2 6q21 C T 0.053 0.981 (0.742 - 1.3) 0.89 
rs16825267 PID1 2q36.3 C G 0.93 1.05 (0.826 - 1.33) 0.70 
rs2076295 DSP 6p24.3 T G 0.49 0.984 (0.879 - 1.1) 0.78 
rs647097 MTCL1 18p11.22 C T 0.40 1.13 (1.01 - 1.27) 0.039 
rs1529672 RARB 3p24.2 C A 0.80 1.08 (0.938 - 1.24) 0.28 
rs721917 SFTPD 10q22.3 G A 0.41 1.13 (1.01 - 1.27) 0.031 
rs12459249 CYP2A6 19q13.2 C T 0.67 1.12 (0.976 - 1.29) 0.11 
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Supplemental Table S6. Summary of prior evidence for genome-wide association of our top 22 loci with either COPD or lung function. 
Novel loci have been highlighted with bold text. 
ICGC Lead 
Variant 
Closest 
Gene Locus 
Prior 
genome-
wide COPD 
locus? 
References for 
COPD association 
Prior COPD SNP 
(LD with ICGC 
variant) 
Consistent 
direction 
of effect? 
Prior 
genome-
wide lung 
function 
locus? 
References for lung 
function association 
Prior lung function 
SNP 
(LD with ICGC 
variant) 
Consistent 
direction 
of effect? 
rs13141641 HHIP 4q31.21 
Pillai et al. (2009), 
Cho et al. (2014) 
rs1828591 (0.98), 
rs13141641 (same) 
YES 
YES  Wilk et al. (2009) rs13147758 (0.90) YES 
rs17486278 CHRNA5 15q25.1 
Pillai et al. (2009), 
Cho et al. (2014) 
rs8034191 (0.90), 
rs12914385 (0.77) 
YES 
YES        
rs7733088 HTR4 5q32  Wilk et al. (2012) rs7733088 (same) YES 
Hancock et al. (2010), 
Repapi et al. (2010) 
rs11168048 (0.90), 
rs3995090 (0.98) 
YES 
YES 
rs9399401 ADGRG6 6q24.1         Hancock et al. (2010) rs3817928 (0.62) YES 
rs1441358 THSD4 15q23         Repapi et al. (2010) rs12899618 (0.29) YES 
rs6837671 FAM13A 4q22.1  Cho et al. (2010) rs7671167 (0.64) YES  Hancock et al. (2010) rs2869967 (1) YES 
rs11727735 GSTCD 4q24  Wain et al. (2015) rs10516528 (1) YES 
Hancock et al. (2010), 
Repapi et al. (2010) 
rs11097901 (1), 
rs10516526 (1) 
YES 
YES 
rs754388 RIN3 14q32.12  Cho et al. (2014) rs754388 (same) YES 
Soler Artigas et al. 
(2015) rs117068593 (0.96) YES 
rs113897301 ADAM19 5q33.3         Hancock et al. (2010) rs2277027 (0.37)** YES 
rs2047409 TET2 4q24         Wain et al. (2015) rs2047409 (same) YES 
rs2955083 EEFSEC 3q21.3               
rs7186831 CFDP1 16q23.1        
Soler Artigas et al. 
(2011) rs2865531 (0.96) YES 
rs10429950 TGFB2 1q41  Cho et al. (2014) rs4846480 (1) YES 
Soler Artigas et al. 
(2011) rs993925 (0.009) NA (no LD) 
rs2070600 AGER 6p21.32        
Hancock et al. (2010), 
Repapi et al. (2010)  rs2070600 (same) YES 
rs17707300 CCDC101 16p11.2 *
Hobbs et al. 
(2016) rs181206 (0.74) YES        
rs2806356 ARMC2 6q21        
Soler Artigas et al. 
(2011) rs2798641 (1) YES 
rs16825267 PID1 2q36.3         Hancock et al. (2010) rs1435867 (1) YES 
rs2076295 DSP 6p24.3               
rs647097 MTCL1 18p11.22               
rs1529672 RARB 3p24.2        
Soler Artigas et al. 
(2011) rs1529672 (same) YES 
rs721917 SFTPD 10q22.3               
rs12459249 CYP2A6 19q13.2  Cho et al. (2012) rs7937 (0.24) YES        
All LD was calculated from 1000 genomes Phase 3 CEU unless otherwise noted. * locus was exome-wide significant. 
** LD was calculated from COPDGene non-Hispanic whites..
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Supplemental Table S7. Details of the four novel COPD association loci. 
 
Lead Novel SNP 
Chr:position (hg19) 
Cytogenetic band 
Lead SNP and SNPs with r2 > 
0.3 (1000 Genomes CEU) 
gene annotations 2 
Details of genes annotated to lead SNPs and SNPs with 
r2 > 0.3 with lead SNP  
Regulatory information via lead 
SNP look-up in HaploReg v4.1 3,4 
NHGRI-EBI GWAS catalog 
query for GWAS loci (P < 
5x10-8) within ± 500 kb of 
lead SNP and with r2 > 0.3 
with lead SNP  
rs2955083 
3:127961178 
3q21.3 
rs2955083 (lead), EEFSEC 
intronic. 
rs11714256 (r2=0.37), 
RUVBL1 intronic. 
rs1042912 (r2=0.37), 
SEC61A1, 3’ UTR. 
rs17203687 (r2=0.31), 
KBTBD12 intronic. 
EEFSEC codes for selenocysteine-specific elongation 
factor, is annotated to GTP and tRNA binding, and is a 
paralog to TUFM 5. 
RUVBL1 codes for RuvB-like 1 protein, which 
participates in ATPase and DNA helicase activity 5. 
SEC61A1 codes for protein transport protein Sec61 
subunit alpha isoform 1, which is associated with 
membrane-bound ribosomes and is important to 
protein translocation 6.  
KBTBD12 codes for the Kelch repeat and BTB domain-
containing protein 12, which is involved in protein 
ubiquitination 5. 
rs2955083 near EEFSEC and 
variants in high LD (r2 > 0.8, 1000 
genomes CEU) possess DNase 
hypersensitivity sites as well as 
promoter and enhancer site 
histone marks across nearly all 
indexed tissue types including 
lung, lung fibroblasts, fetal lung, 
and fetal lung fibroblasts. 
Additionally, 25 different 
regulatory motifs are altered by 
rs2955083. 
rs2687729 (r2=1.0), 
menarche age at onset 7 
rs2999052 (r2=0.38), 
hypospadias 8 
rs10934853 (r2=0.33),  
prostate cancer 9 
rs2076295 
6:7563232 
6p24.3 
rs2076295 (lead), 
DSP intronic. 
(No SNPs with r2 > 0.3 in any 
additional genes) 
DSP codes for desmoplakin, a major protein of 
desmosomes 5, which is required for epidermal 
integrity 10. DSP mutations have been linked to several 
Mendelian syndromes involving palmoplantar 
keratoderma 11, left ventricular cardiomyopathy 12, 
familial arrhythmogenic right ventricular dysplasia 13, 
and lethal ancantholytic epidermolysis bullosa 14.  
Further, our lead SNP in DSP has been previously 
associated with fibrotic idiopathic interstitial 
pneumonias in GWAS 15; however, the minor allele for 
rs2076295 has opposite direction of effect for 
pulmonary fibrosis and COPD risk.. 
rs2076295  reported to have 
DNase hypersensitivity sites and 
enhancer histone marks in blood 
and several solid organs; 
however, none in lung tissues 
rs2076295 (lead), 
interstitial lung disease 
15,16 
rs647097 
18:8808464 
18p11.22 
rs647097 (lead), MTCL1 
intronic. 
(No SNPs with r2 > 0.3 in any 
additional genes) 
MTCL1 codes for the microtubule cross-linking factor 
1, important in epithelial-cell-specific microtubule 
stabilization and accumulation around the Golgi 
apparatus 17,18.  
rs647097 and variants in high 
LD (r2 > 0.8 in 1000 genomes 
phase 1 CEU) have enhancer 
histone marks in fetal lung 
fibroblasts. Several regulatory 
motifs are altered by rs647097 None. 
rs721917 
10:81706324 
10q22.3 
rs721917 (lead), SFTPD 
non-synonymous (missense).  
(No SNPs with r2 > 0.3 in any 
additional genes) 
SFTPD codes for the pulmonary surfactant-associated 
protein D, which functions in lung innate immunity 5. 
Sftpd (-/-) mice have been observed to have chronic 
inflammation, emphysema, and fibrosis 19. SFTPD 
variants have been examined in a COPD candidate 
gene study 20 and SFTPD levels have been research as 
a COPD biomarker 21. 
rs721917 has enhancer histone 
marks in fetal lung tissue 
rs1923539 (r2=0.38), 
circulating surfactant 
protein D levels in COPD 22 
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Supplemental Table S8. Full results (P < 0.05 in meta-analysis) for lung expression quantitative 
trait locus (eQTL) analysis. All cis- and trans- eQTL with P < 0.05 in meta-analysis are shown. eQTL 
associations meeting Bonferroni correction of P < 5.2x10-8 are highlighted.  * refers to proxy 
variant. Supplemental Table S8 is attached in Excel format “icgcSuppTableS8_fullEqtlResults.xlsx”. 
 
  
 
 
57 
Supplemental Table 9a-b: Co-localization results. Probe = affymetrix probe ID, tile center 
given as chromosome position for hg19. ppH4 = posterior probability of co-localization of the 
GWAS and eQTL association. Results with posterior probability of co-localization > 0.6 are 
shown. 
 
Supplemental Table 9a: Co-localization using the Lung eQTL data23.  
Probe Gene  Tile center ppH4 
100149674_TGI_at RARB 3:25520582 0.85 
100139086_TGI_at NA 4:145506456 0.95 
100311674_TGI_at HHIP 4:145506456 0.95 
100133899_TGI_at NA 4:145506456 0.94 
100148028_TGI_at HHIP 4:145506456 0.94 
100312038_TGI_at FAM13A 4:89873092 0.77 
100313510_TGI_at AGER 6:32151443 0.93 
100131291_TGI_at NA 6:7563232 0.99 
100304914_TGI_at DSP 6:7563232 0.99 
100313405_TGI_at DSP 6:7563232 0.99 
100125626_TGI_at TGFB2 1:218624533 0.62 
100142979_TGI_at THSD4 15:71612514 0.99 
100308491_TGI_at THSD4 15:71612514 0.99 
100310339_TGI_at THSD4 15:71612514 0.99 
100130228_TGI_at NA 15:71612514 0.68 
100123649_TGI_at CHRNA3 15:78867482 0.89 
100129347_TGI_at SBK1 16:28593347 0.79 
100142003_TGI_at SPNS1 16:28593347 0.67 
100300284_TGI_at MTCL1 18:8808464 0.76 
 
Supplemental Table 9b: Co-localization using lung tissue from GTEx24.  
ensembleID Gene Tile center ppH4 
ENSG00000270720.1 RP11-84C13.2 4:89373092 0.75 
ENSG00000135074.11 ADAM19 5:156429077 0.79 
ENSG00000248544.2 CTB-47B11.3 5:156429077 0.67 
ENSG00000176476.4 SGF29 16:28093347 0.89 
ENSG00000178188.10 SH2B1 16:28093347 0.79 
ENSG00000196502.7 SULT1A1 16:28093347 0.75 
ENSG00000264455.1 MIR4721 16:28093347 0.7 
ENSG00000168502.13 MTCL1 18:8308464 0.92 
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Supplemental Table S10. Sensitivity analysis results for COPD association of top 22 loci using Post- versus Pre-Bronchodilator Definitions of 
COPD in the COPDGene NHW and AA, ECLIPSE, NETT-NAS, and Norway/GenKOLS cohorts. 
Location rsID 
Beta P 
Post- Pre- Post- Pre- 
4:145506456 rs13141641 0.23 0.23 7.80E-10 1.10E-09 
15:78867482 rs17486278 0.22 0.23 5.10E-10 6.40E-11 
5:147856333 rs7733088 0.08 0.09 0.027 0.0094 
6:142668901 rs9399401 0.11 0.11 0.0026 0.0026 
15:71612514 rs1441358 0.1 0.13 0.0037 0.00026 
4:89873092 rs6837671 0.24 0.22 2.70E-12 7.40E-11 
4:106631870 rs11727735 0.26 0.26 7.00E-04 0.00074 
14:93115410 rs754388 0.24 0.23 1.80E-07 4.60E-07 
5:156929077 rs113897301 0.1 0.1 0.032 0.037 
4:106137033 rs2047409 0.1 0.09 0.0037 0.0091 
3:127961178 rs2955083 0.27 0.26 2.40E-07 1.20E-06 
16:75473155 rs7186831 0.09 0.1 0.027 0.019 
1:218624533 rs10429950 0.14 0.14 0.00025 0.00012 
6:32151443 rs2070600 0.34 0.25 0.00023 0.0068 
16:28593347 rs17707300 0.14 0.14 1.00E-04 0.00018 
6:109266255 rs2806356 0.14 0.12 0.0026 0.0087 
2:229569919 rs16825267 0.26 0.2 7.50E-05 0.0022 
6:7563232 rs2076295 0.13 0.14 8.40E-05 5.40E-05 
18:8808464 rs647097 0.07 0.07 0.049 0.052 
3:25520582 rs1529672 0.12 0.1 0.0059 0.023 
10:81706324 rs721917 0.09 0.07 0.0072 0.028 
19:41339896 rs12459249 0.11 0.14 0.0059 0.00055 
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Supplemental Table S11. Look-up of NHGRI-EBI GWAS Catalog asthma-associated trait genome-wide significant GWAS loci in our COPD 
association Stage 1 meta-analysis results. Supplemental Table S1 is attached in Excel format “icgcSuppTableS11_asthmaGwasCopdAssoc.xlsx”. Only 
asthma trait GWAS loci that were present in our Stage 1 analysis are reported. 
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Supplemental Table S12. Association of top 22 COPD association loci from overall meta-analysis in the GABRIEL Consortium asthma GWAS25 
Chr SNP* 
Asthma OR 
(Random 
Effects) 
Asthma P Value 
(Random 
Effects) 
Proxy 
SNP 
Used? 
COPD Index 
SNP 
LD (r2) with 
COPD Index 
SNP 
1 rs10429950 1.01 0.61 NO -- -- 
3 rs1529672 1.03 0.27 NO -- -- 
3 rs2811518 0.93 0.026 YES rs2955083 1 
4 rs2869967 1.02 0.44 YES rs6837671 0.97 
4 rs1391441 0.99 0.69 YES rs2047409 0.90 
4 rs11727735 0.96 0.26 NO -- -- 
4 rs6817273 1.02 0.36 YES rs13141641 0.93 
5 rs3995090 0.98 0.29 YES rs7733088 0.97 
5 rs3734031 1.03 0.48 YES rs56168343 0.56 
6 rs2076295 1.00 0.86 NO -- -- 
6 rs2070600 1.01 0.92 NO -- -- 
6 rs2798641 1.03 0.18 YES rs2806356 1 
6 rs6570507 1.03 0.16 YES rs9399401 0.96 
10 rs721917 0.98 0.38 NO -- -- 
14 rs11627032 1.03 0.26 YES rs754388 0.63 
15 rs6494904 1.00 0.84 YES rs1441358 0.75 
15 rs1051730 0.99 0.64 YES rs17486278 0.93 
16 rs4788073 1.00 0.92 YES rs17707300 1 
18 rs647097 1.04 0.13 NO -- -- 
19 rs7251418 0.99 0.86 YES rs12459249 0.88 
 No proxy SNPs with r2 > 0.5 could be found for top COPD SNPs rs7186831 (CFDP1) and rs16825267 (PID1)  
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Supplemental Table S13. Look-up of NHGRI-EBI GWAS Catalog “Nicotine Dependence” and “Smoking Behaviors” genome-wide significant GWAS 
loci in our COPD association Stage 1 meta-analysis results. 
Chr Position SNP Region 
NHGRI-EBI Catalog 
Mapped Genes 
Effect 
Allele 
Average Effect 
Allele Freq OR (COPD) 
P value 
(COPD) 
1 99445471 rs61784651 1p21.1 LPPR5 T 0.15 0.98 0.55 
2 146316319 rs10193706 2q22.3 TEX41 - PABPC1P2 A 0.50 0.96 0.032 
6 38901867 rs10807199 6p21.2 DNAH8 T 0.45 1.00 0.95 
8 42546711 rs1451240 8p11.21 SMIM19 - LOC105379396 A 0.29 0.96 0.086 
8 42550498 rs6474412 8p11.21 SMIM19 - LOC105379396 T 0.72 1.05 0.045 
9 136478355 rs3025343 9q34.2 FAM163B - DBH A 0.11 1.03 0.43 
10 93348120 rs1329650 10q23.32 HECTD2-AS1 T 0.27 1.02 0.33 
11 27679916 rs6265 11p14.1 BDNF - BDNF-AS T 0.20 1.03 0.24 
11 112861434 rs4466874 11q23.2 NCAM1 T 0.59 0.98 0.40 
15 78851615 rs2036527 15q25.1 PSMA4 - CHRNA5 A 0.34 1.20 2.2E-18 
15 78894339 rs1051730 15q25.1 CHRNA3 A 0.34 1.21 2.8E-22 
19 41310571 rs3733829 19q13.2 EGLN2 - RAB4B-EGLN2 A 0.65 0.96 0.030 
19 41363765 rs8102683 19q13.2 CYP2A6 - CYP2A7 T 0.25 0.95 0.017 
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Supplemental Table S14. Association of top 22 COPD loci from overall meta-analysis in the cigarettes per day (cig/day) GWAS by the Tobacco and 
Genetics Consortium26 
Chr SNP 
Effect 
Allele 
Effect 
Allele 
Freq 
Effect 
Size 
(cig/day) 
Standard 
Error 
P Value 
(Cig/day) 
Proxy 
SNP 
Used? 
COPD Index 
SNP 
LD (r2) 
with COPD 
Index SNP 
1 rs10429950 T 0.72 -0.012 0.091 0.90 NO -- -- 
2 rs16825267 C 0.93 -0.037 0.17 0.83 NO -- -- 
3 rs1529672 A 0.17 0.0038 0.11 0.97 NO -- -- 
3 rs2999073 C 0.88 -0.078 0.13 0.56 YES rs2955083 1 
4 rs2045517 T 0.40 -0.069 0.083 0.40 YES rs6837671 0.97 
4 rs2047409 A 0.62 -0.067 0.084 0.42 NO -- -- 
4 rs11727735 A 0.93 0.12 0.16 0.48 NO -- -- 
4 rs13141641 T 0.58 0.21 0.083 0.012 NO -- -- 
5 rs7733088 A 0.38 0.034 0.094 0.72 NO -- -- 
5 rs3734031 A 0.90 -0.098 0.13 0.46 YES rs56168343 0.56 
6 rs2076295 T 0.55 0.022 0.084 0.79 NO -- -- 
6 rs2070600 T 0.04 0.069 0.21 0.74 NO -- -- 
6 rs2806356 T 0.81 0.031 0.10 0.77 NO -- -- 
6 rs9399401 T 0.70 0.077 0.089 0.39 NO -- -- 
10 rs721917 A 0.58 -0.12 0.083 0.15 NO -- -- 
14 rs754388 C 0.82 -0.14 0.12 0.23 NO -- -- 
15 rs11853359 A 0.33 0.059 0.087 0.50 YES rs1441358 0.98 
15 rs17486278 A 0.65 -1.04 0.087 5.91E-33 NO -- -- 
16 rs17707300 T 0.63 -0.030 0.085 0.72 NO -- -- 
18 rs647097 T 0.74 -0.12 0.092 0.18 NO -- -- 
19 rs7251418 A 0.28 -0.21 0.16 0.19 YES rs12459249 0.88 
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Supplemental Table S15. Association of top 22 COPD loci from overall meta-analysis in the ever-smoking GWAS by the Tobacco and Genetics 
Consortium26 
Chr SNP 
Effect 
Allele 
Effect 
Allele 
Freq 
OR 
(Ever-
Smoking) 
P Value 
(Ever-
Smoking) 
Proxy SNP 
Used? 
COPD Index 
SNP 
LD (r2) 
with COPD 
Index SNP 
1 rs10429950 T 0.71 1.00 0.84 NO -- -- 
2 rs16825267 C 0.89 0.97 0.24 NO -- -- 
3 rs1529672 A 0.20 0.99 0.66 NO -- -- 
3 rs2999073 C 0.84 1.03 0.18 YES rs2955083 1 
4 rs2045517 T 0.41 0.98 0.18 YES rs6837671 0.97 
4 rs2047409 A 0.61 1.02 0.058 NO -- -- 
4 rs11727735 A 0.91 0.98 0.38 NO -- -- 
4 rs13141641 T 0.57 1.00 0.89 NO -- -- 
5 rs7733088 A 0.39 0.99 0.61 NO -- -- 
5 rs3734031 A 0.87 0.96 0.024 YES rs56168343 0.56 
6 rs2076295 T 0.54 0.98 0.038 NO -- -- 
6 rs2070600 T 0.07 1.02 0.42 NO -- -- 
6 rs2806356 T 0.79 0.99 0.41 NO -- -- 
6 rs9399401 T 0.69 1.00 0.72 NO -- -- 
10 rs721917 A 0.57 1.00 0.68 NO -- -- 
14 rs754388 C 0.79 1.01 0.74 NO -- -- 
15 rs11853359 A 0.34 0.98 0.17 YES rs1441358 0.98 
15 rs17486278 A 0.65 1.00 0.94 NO -- -- 
16 rs17707300 T 0.62 1.00 0.95 NO -- -- 
18 rs647097 T 0.72 1.00 0.89 NO -- -- 
19 rs7251418 A 0.28 1.02 0.38 YES rs12459249 0.88 
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Supplemental Table S16. Look-up of NHGRI-EBI GWAS Catalog coronary artery disease and osteoporosis-related genome-wide significant GWAS 
loci in our COPD association Stage 1 meta-analysis results. Only comorbidity loci with COPD P value < 0.05 are reported. 
SNP Region Trait 
GWAS Reference 
PMID Mapped Gene 
Comorbid 
Trait Risk 
Allele 
Freq of Comorbid 
Trait Risk Allele in 
COPD 
COPD OR (95% CI) for 
Comorbid Trait Risk Allele 
COPD 
Association 
P value 
rs3825807 15q25.1 Coronary heart disease 21378990 ADAMTS7 A 0.576 0.927 (0.891 - 0.964) 1.5E-04 
rs1994016 15q25.1 Coronary artery disease 21239051 ADAMTS7 C 0.608 0.93 (0.892 - 0.97) 6.9E-04 
rs4380028 15q25.1 Coronary heart disease 21378988 
ADAMTS7 -  
TRK-CTT1-2 C 0.605 0.94 (0.906 - 0.975) 0.0010 
rs974819 11q22.3 Coronary heart disease 21378988 
LOC105369463 - 
LOC102723862 T 0.332 0.938 (0.902 - 0.976) 0.0014 
rs2128739 11q22.3 Coronary artery disease 26343387 
LOC105369463 - 
LOC102723862 A 0.311 0.94 (0.901 - 0.98) 0.0037 
rs13336428 16p13.3 Bone mineral density 22504420 CLCN7 - PTX4 A 0.447 0.942 (0.904 - 0.982) 0.0045 
rs228769 17q21.31 
Bone mineral density 
(hip) 19801982 
LOC105371789 - 
HDAC5 G 0.261 0.938 (0.896 - 0.982) 0.0062 
rs7932354 11p11.2 
Bone mineral density 
(hip) 19801982 
ARHGAP1 - 
ZNF408 T 0.345 1.06 (1.01 - 1.11) 0.0097 
rs2519093 9q34.2 Coronary artery disease 26343387 ABO T 0.192 1.06 (1.01 - 1.11) 0.018 
rs56062135 15q22.33 Coronary artery disease 26343387 SMAD3 C 0.774 0.946 (0.901 - 0.992) 0.024 
rs579459 9q34.2 Coronary heart disease 21378990 ABO - SURF6 C 0.215 1.05 (1.01 - 1.1) 0.028 
rs10048146 16q24.1 
Bone mineral density 
(spine) 19801982 
LOC105371390 - 
LOC105371391 G 0.187 1.05 (1.01 - 1.11) 0.029 
rs16921914 11p13 
Bone mineral density 
(spine) 19801982 DCDC5 - DCDC1 A 0.279 1.05 (1 - 1.09) 0.030 
rs964184 11q23.3 Coronary heart disease 21378990 
LOC105369514 - 
ZPR1 G 0.152 0.945 (0.898 - 0.995) 0.032 
rs6689306 1q21.3 Coronary artery disease 26343387 IL6R A 0.412 0.958 (0.92 - 0.997) 0.034 
rs736825 12q13.13 Bone mineral density 22504420 
HOXC5 - HOXC4 - 
HOXC6 C 0.643 0.956 (0.917 - 0.997) 0.035 
rs4468572 15q25.1 Coronary artery disease 26343387 
ADAMTS7 -  
TRK-CTT1-2 C 0.566 0.958 (0.921 - 0.997) 0.036 
rs344081 3q25.31 Bone mineral density 22504420 LEKR1 T 0.787 1.06 (1 - 1.12) 0.043 
rs163879 11p14.1 Bone mineral density 22504420 DCDC5 T 0.651 0.96 (0.921 - 1) 0.048 
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Supplemental Table S17. Quantitative imaging GWAS results27 for each of the 22 genome-wide significant loci from our COPD association overall 
meta-analysis. 
        Emphysema Airways 
rsID 
Closest 
Gene Locus 
COPD 
Risk 
Allele 
%LAA-950 
Beta (95% CI) 
%LAA-
950 
P Value 
Perc15 
Beta (95% CI) 
Perc15 
P Value 
Pi10 
Beta (95% CI) 
Pi10 
P Value 
Wall Area Percent 
Beta (95% CI) 
Wall Area 
Percent 
P Value 
rs13141641 HHIP 4q31.21 T 0.12 (0.16, 0.091) 1.7E-12 -2.2 (-1.5, -2.9) 8.4E-10 -4e-04 (0.0033, -0.0041) 0.41 0.1 (0.19, 0.016) 0.027 
rs17486278 CHRNA5 15q25.1 C 0.094 (0.13, 0.06) 4.9E-08 -1.4 (-0.75, -2.1) 4.4E-05 0.0031 (0.0066, -0.00043) 0.099 0.0036 (0.089, -0.082) 0.41 
rs7733088 HTR4 5q32 G 0.022 (0.056, -0.011) 0.24 -0.5 (0.2, -1.2) 0.20 0.002 (0.0055, -0.0015) 9.5E-03 0.16 (0.24, 0.076) 2.7E-04 
rs9399401 ADGRG6 6q24.1 T 0.065 (0.1, 0.031) 3.1E-04 -1.2 (-0.47, -1.9) 1.6E-03 -0.0013 (0.0024, -0.005) 0.27 0.021 (0.11, -0.067) 0.59 
rs1441358 THSD4 15q23 G 0.05 (0.082, 0.017) 4.1E-03 -0.91 (-0.22, -1.6) 0.012 -1e-04 (0.0034, -0.0036) 0.96 0.043 (0.13, -0.041) 0.38 
rs6837671 FAM13A 4q22.1 G 0.066 (0.098, 0.034) 8.4E-05 -1.2 (-0.55, -1.9) 1.6E-04 0.0036 (0.0071, 7.2e-05) 0.0525 0.13 (0.21, 0.05) 2.1E-03 
rs11727735 GSTCD 4q24 A 0.036 (0.11, -0.036) 0.30 -0.67 (0.8, -2.1) 0.27 0.012 (0.019, 0.0038) 5.7E-03 0.39 (0.57, 0.21) 4.47E-05 
rs754388 RIN3 14q32.12 C 0.093 (0.14, 0.05) 2.7E-05 -1.8 (-0.96, -2.7) 5.5E-05 0.0021 (0.0068, -0.0026) 0.45 0.11 (0.22, 0.0018) 0.040 
rs2047409 TET2 5q33.3 A 0.034 (0.067, 0.0018) 0.012 -0.78 (-0.1, -1.5) 0.016 -3e-04 (0.0032, -0.0038) 0.92 0.058 (0.14, -0.026) 0.21 
rs2955083 EEFSEC 4q24 A 0.058 (0.11, 0.0085) 0.029 -0.96 (0.075, -2) 0.087 0.0095 (0.015, 0.0042) 6.7E-04 0.093 (0.22, -0.033) 0.19 
rs56168343* ADAM19 3q21.3 T 0.052 (0.098, 0.007) 0.031 -1.3 (-0.38, -2.2) 7.7E-03 0.0022 (0.0073, -0.0029) 0.45 0.037 (0.15, -0.079) 0.60 
rs7186831 CFDP1 16q23.1 A 0.0095 (0.049, -0.03) 0.45 -0.023 (0.8, -0.85) 0.98 0.0053 (0.0096, 0.00099) 0.020 0.14 (0.24, 0.036) 0.011 
rs10429950 TGFB2 1q41 T 0.08 (0.11, 0.045) 1.1E-05 -1.3 (-0.6, -2.1) 4.9E-04 0 (0.0037, -0.0037) 0.99 0.084 (0.17, -0.0057) 0.087 
rs2070600 AGER 6p21.32 C 0.24 (0.32, 0.15) 4.6E-09 -3.8 (-2, -5.5) 2.2E-06 -0.0036 (0.0058, -0.013) 0.53 0.073 (0.29, -0.15) 0.58 
rs17707300 CCDC101 16p11.2 C 0.0051 (0.039, -0.029) 0.83 0.28 (0.98, -0.42) 0.49 0.0035 (0.0072, -0.00022) 0.085 0.055 (0.14, -0.032) 0.26 
rs2806356 ARMC2 6q21 C 0.02 (0.064, -0.023) 0.42 -0.36 (0.54, -1.3) 0.49 0.0039 (0.0086, -8e-04) 0.13 0.19 (0.31, 0.082) 9.5E-04 
rs16825267 PID1 2q36.3 C 0.082 (0.14, 0.019) 0.014 -1.7 (-0.38, -3) 0.015 -4e-04 (0.0063, -0.0071) 0.94 0.023 (0.18, -0.14) 0.83 
rs2076295 DSP 6p24.3 T 0.031 (0.063, -0.00085) 0.014 -0.64 (0.014, -1.3) 0.066 -0.0012 (0.0021, -0.0045) 0.57 0.035 (0.12, -0.046) 0.46 
rs647097 MTCL1 18p11.22 C -0.001 (0.034, -0.036) 0.093 0.03 (0.75, -0.69) 0.32 0.0012 (0.0049, -0.0025) 0.59 0.077 (0.16, -0.011) 0.11 
rs1529672 RARB 3p24.2 C 0.07 (0.11, 0.029) 8.4E-04 -1.7 (-0.81, -2.5) 2.0E-04 0.0012 (0.0057, -0.0033) 0.47 0.092 (0.2, -0.014) 0.11 
rs721917 SFTPD 10q22.3 G 0.0099 (0.042, -0.022) 0.62 -0.085 (0.58, -0.75) 0.86 3e-04 (0.0036, -0.003) 0.71 0.07 (0.15, -0.012) 0.12 
rs12459249 CYP2A6 19q13.2 C 0.073 (0.11, 0.035) 2.2E-04 -1.2 (-0.46, -2) 2.4E-03 8e-04 (0.0049, -0.0033) 0.78 0.08 (0.18, -0.016) 0.14 
* The indel rs113897301 was not available in the quantitative imaging results, so rs56168343, the second most significant variant at the 3q21.3 
locus, was used as a proxy. 
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Supplemental Table S18. For each of the 22 genome-wide significant loci, the highest LD (r2) 
proxy SNP that was present in HapMap phase III was chosen as the input variant for the PrixFixe 
method of gene prioritization. 
Chr:position 
index variant 
Chr:position 
HapMap III 
proxy variant 
rsID 
HapMap III 
proxy variant 
P value of 
proxy variant* 
LD (r2) 
between 
index and 
proxy 
1:218624533 1:218624533 rs10429950 1.83E-07 1.00 
2:229569919 2:229592304 rs3732192 1.78E-07 0.99 
3:127961178 3:127991938 rs2811416 3.91E-07 1.00 
3:25520582 3:25520582 rs1529672 2.37E-09 1.00 
4:106137033 4:106131210 rs2007403 3.32E-06 1.00 
4:106631870 4:106631870 rs11727735 1.55E-08 1.00 
4:145506456 4:145474473 rs1489759 5.48E-15 0.92 
4:89873092 4:89869332 rs2869967 1.55E-14 0.99 
5:147856333 5:147856333 rs7733088 4.41E-14 1.00 
5:156929077:ID 5:156932376 rs2277027 8.31E-06 0.37 
6:109266255 6:109268050 rs2798641 1.46E-05 1.00 
6:142668901 6:142670955 rs7756305 1.52E-08 1.00 
6:32151443 6:32062687 rs2071293 4.12E-03 0.01 
6:7563232 6:7563232 rs2076295 4.95E-08 1.00 
10:81706324 10:81706324 rs721917 2.11E-06 1.00 
14:93115410 14:93111120 rs11624512 7.76E-11 0.99 
15:71612514 15:71612514 rs1441358 2.06E-10 1.00 
15:78867482 15:78878541 rs951266 1.72E-23 0.99 
16:28593347 16:28593347 rs17707300 6.25E-09 1.00 
16:75473155 16:75479153 rs2161684 2.85E-04 0.62 
18:8808464 18:8808464 rs647097 3.03E-06 1.00 
19:41339896 19:41341589 rs7251418 1.93E-03 0.85 
* The COPD association Stage 1 meta-analysis P value for the HapMap III compatible proxy variant. 
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Supplemental Table S19. Gene prioritization scores using PrixFixe method of identifying co-
functional genes across the genome-wide significant loci in our study. 
Gene Region 
PrixFixe 
Score   Gene Region 
PrixFixe 
Score 
TGFB2 chr1:q41 0.480   CHRNB4 chr15:q25.1 0.262 
RARB chr3:p24.2 0.188   PSMA4 chr15:q25.1 0.261 
RUVBL1 chr3:q21.3 0.160   CHRNA3 chr15:q25.1 0.124 
EEFSEC chr3:q21.3 0.021   CHRNA5 chr15:q25.1 0.104 
FAM13A chr4:q22.1 0.164   IREB2 chr15:q25.1 0.057 
PPA2 chr4:q24 0.179   CLN3 chr16:p11.2 0.333 
TET2 chr4:q24 0.056   NUPR1 chr16:p11.2 0.157 
HHIP chr4:q31.21 0.184   CCDC101 chr16:p11.2 0.115 
HTR4 chr5:q32 0.026   IL27 chr16:p11.2 0.111 
ADAM19 chr5:q33.3 0.129   APOBR chr16:p11.2 0.078 
CFB chr6:p21.32--p21.33 0.199   SULT1A2 chr16:p11.2 0.071 
TNXB chr6:p21.32--p21.33 0.187   SULT1A1 chr16:p11.2 0.070 
EGFL8 chr6:p21.32--p21.33 0.111   BCAR1 chr16:q23.1 0.135 
C2 chr6:p21.32--p21.33 0.083   GABARAPL2 chr16:q23.1 0.107 
SLC44A4 chr6:p21.32--p21.33 0.052   CFDP1 chr16:q23.1 0.076 
EHMT2 chr6:p21.32--p21.33 0.051   CHST6 chr16:q23.1 0.057 
RNF5 chr6:p21.32--p21.33 0.022   TMEM170A chr16:q23.1 0.053 
CYP21A2 chr6:p21.32--p21.33 0.011   CTRB2 chr16:q23.1 0.047 
CYP21A1P chr6:p21.32--p21.33 0.009   CCDC165 chr18:p11.22 0.031 
LSM2 chr6:p21.32--p21.33 0.008   EGLN2 chr19:q13.2 0.135 
RDBP chr6:p21.32--p21.33 0.006   NUMBL chr19:q13.2 0.080 
DSP chr6:p24.3 0.259   CYP2A6 chr19:q13.2 0.067 
SNRNP48 chr6:p24.3 0.007   SNRPA chr19:q13.2 0.055 
GPR126 chr6:q24.1--q24.2 0.053   ADCK4 chr19:q13.2 0.025 
SFTPD chr10:q22.3 0.321   MIA chr19:q13.2 0.018 
C10orf57 chr10:q22.3 0.073   ITPKC chr19:q13.2 0.011 
RIN3 chr14:q32.12 0.102   CYP2G1P chr19:q13.2 0.002 
THSD4 chr15:q23 0.164   C19orf54 chr19:q13.2 0.002 
The 2q36.2 locus (rs16825267; closest gene PID1) is not present in PrixFixe's cofunction networks, 
and is consequently not represented in the table. 
*Genes with PrixFixe prioritization score of "0" are not shown. Thus, the 6q21 locus (rs2806356; 
closest genes ARMC2) is not represented in the table. 
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Supplemental Table S20: Results of fine-mapping analysis (see text). 
Chr:Pos 
Index variant 
European GWAS 
African-American GWAS 
Top variant P < 0.001 
Markers in 
95% credible 
set 
Posterior 
probability, 
top-ranked 
marker 
r2 
(with top 
overall 
variant) 
D’ 
(with top 
overall 
variant) 
Present in 
European 
credible set 
1:218624533 121 0.13 4.30E-02 0.42 N 
2:229569919 29 0.11 7.30E-04 0.45 N 
3:127961178 192 0.043 
   
3:25520582 10 0.61 1.10E-03 0.057 N 
4:106137033 29 0.17 
   
4:106631870 267 0.033 
   
4:145506456 29 0.66 7.90E-02 0.71 N 
4:89873092 9 0.85 1.40E-03 0.085 N 
5:147856333 19 0.36 
   
5:156929077 1 0.99 4.30E-05 0.014 N 
6:109266255 384 0.28 7.30E-03 1 N 
6:142668901 71 0.057 
   
6:32151443 30 0.37 
   
6:7563232 8 0.52 
   
10:81706324 1193 0.15 4.20E-01 0.93 Y 
14:93115410 16 0.24 
   
15:71612514 37 0.44 3.40E-01 0.93 N 
15:78867482 18 0.37 1.90E-03 0.082 N 
16:28593347 97 0.11 
   
16:75473155 542 0.22 2.20E-01 0.72 Y 
18:8808464 172 0.29 
   
19:41339896 22 0.52 2.10E-02 0.39 N 
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Supplemental Methods: 
 
Cohort descriptions and cohort-specific methods 
 
ARIC: Atherosclerosis Risk in Communities (ARIC)28 (NCT00005131), is a population based study 
of risk factors for atherosclerosis and its sequelae in adults from four U.S. field centers aged 45-64 
at recruitment in 1987-1989. Institutional Review Board (IRB) approval was obtained at all 
associated study centers and informed consent was obtained for all participants. ARIC spirometry 
measurements were made with a Collins Survey II water-seal spirometer (Collins Medical, Inc.) and 
Pulmo-Screen II software (PDS Healthcare Products, Inc.). Genotyping was done using the 
AffymetrixGeneChip SNP Array 6.0 and imputation was performed using IMPUTE2. Quality control 
steps for genotyping data included exclusions for call rate <95%, minor allele frequency <1%, HWE 
P<10-5, no chromosomal location, suspected first-degree relative of an included individual based 
on genotype data, or more than 8 standard deviations for any of the first ten principal components. 
The current analysis includes 7,224 Caucasian subjects with genotyping data, pulmonary function 
measures and complete covariate information. Imputation was performed using the 1000 
Genomes29 cosmopolitan reference panel, Phase I v3, using MaCH30,31.  Logistic regression was 
performed using ProbABEL32 v0.1-3. 
 
B58C: The British 1958 birth cohort is a long-term follow-up of persons born in England, Scotland 
and Wales during one week in 1958. At age 44-45 years, cohort members were invited to 
participate in a biomedical examination in their home at which spirometry was performed in the 
standing position, without noseclips, using a Vitalograph Micro spirometer. Informed consent was 
obtained for all participants and ethical approval for the medical examination of the British 1958 
Birth Cohort was obtained from the South-East Multicentre Research Ethics Committee (SE-MREC). 
Details of this fieldwork and the spirometric protocol have been published elsewhere33,34. At the 
same examination, blood samples were collected with consent for DNA extraction and production 
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of immortalized cell lines. The resulting DNA collection has been widely used as a nationally 
representative reference set, including the Wellcome Trust Case-Control Consortium35, the Type 1 
Diabetes Genetic Consortium36 and the GABRIEL asthma consortium25. Genotyping platform was 
performed using Illumina 550K/610K.  Imputation was performed using the 1000 Genomes29 
March 2012, cosmopolitan reference panel and MaCH/minimac30,31,37. ProbABEL32 0.1-9 was used 
for analysis. 
Cardiovascular Health Study (CHS): The Cardiovascular Health Study (CHS) is a population-based 
cohort study of risk factors for coronary heart disease and stroke in adults ≥65 years conducted 
across four field centers38 (NCT00005133 and NCT00149435). Local IRB approval was obtained at 
participating centers and written informed consent was obtained for all participants. The original 
predominantly European ancestry cohort of 5,201 persons was recruited in 1989-1990 from 
random samples of the Medicare eligibility lists; subsequently, an additional predominantly 
African-American cohort of 687 persons were enrolled for a total sample of 5,888.  Blood samples 
were drawn from all participants at their baseline examination and DNA was subsequently 
extracted from available samples. European ancestry participants were excluded from the GWAS 
study sample due to the presence at study baseline of coronary heart disease, congestive heart 
failure, peripheral vascular disease, valvular heart disease, stroke or transient ischemic 
attack. Genotyping was performed at the General Clinical Research Center’s 
Phenotyping/Genotyping Laboratory at Cedars-Sinai among CHS participants who consented to 
genetic testing and had DNA available using the Illumina 370CNV BeadChip system (for European 
ancestry participants, in 2007) or the Illumina HumanOmni1-Quad_v1 BeadChip system (for 
African-American participants, in 2010). Additional genotypes were provided from the ITMAT-
Broad-CARe (IBC) Illumina iSELECT chip. Imputation was performed using 1000 Genomes29 Phase 
1 v3 haplotypes and minimac37 (2012-11-16).  Logistic regression was performed in R, adjusting for 
CHS clinic (4 sites) and PCs 1-5. 
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COPD Pathology: Addressing Critical gaps, Early Treatment & 
Diagnosis and Innovative Concepts (COPACETIC):  The COPACETIC39 cohort includes Dutch (all 
Caucasian-ancestry) participants from the NELSON40 lung cancer screening trial recruited by the 
University Medical Centers of Groningen and Utrecht. The trials were approved by the Dutch 
Minister of Health and the ethics board at each participating centre. All participants gave written 
informed consent. All participants were substantial smokers (16.5 or more pack-years) aged 
between 50–75 years. Pre-bronchodilator pulmonary function tests were performed with 
standardized equipment according to the American Thoracic Society (ATS) and European 
Respiratory Society (ERS) guidelines. All participants provided written informed consent.  Blood 
samples were genotyped using the Illumina 610 Quad BeadChip. Genotype calling was done with 
the standard algorithm provided by Illumina and implemented in GenomeStudio software. Quality 
control was performed using PLINK41 software. Samples were excluded if more than 5% of 
genotype data was missing (n = 19), if samples were duplicated (n = 29), detected as an ethnic 
outlier (based on genetic distance derived from principal components c1 and c2; n = 49), derived 
from a relative of another participant (based on IBS estimation, Phat > 0.5, n= 13), or if the 
participant had a diagnosis of lung cancer (n =16). Imputation was performed using the Impute2 
pipeline developed by the GoNL - Impute team. In summary: The study data was lifted over from 
human genome build 36 to build 37 using PLINK and UCSC liftOver, followed by alignment to 
reference data and filtering on MAF larger than 1%, Hardy-Weinberg Equilibrium p-value of 1e-4 
and a call rate higher than 0.95. Afterwards the study data was pre-phased per chromosome using 
SHAPEIT2 v.2.64442. Finally the imputation over genome chunks of 5Mb was performed using 
IMPUTE2 2.3.043.  1000 Genomes29 phase1 integrated version 3 was used as reference panel.  
Associations between genomic dosages with moderate/severe COPD were assessed with logistic 
regression models adjusted for age, pack years smoked, and sex; current smoking status was not 
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available at the time of analysis. All analysis were performed in software package PLINK version 
1.0741,44.    
 
COPDGene: Details of the COPDGene Study (NCT00608764, www.copdgene.org) have been 
described previously45,46. Local IRB approval was obtained at all study centers and all study 
participants provided written informed consent. Eligible subjects were of non-Hispanic white or 
African-American ancestry, aged 45-80 years old, with a minimum of 10 pack-years of smoking and 
no lung disease (other than COPD or asthma). Genotyping was performed by Illumina (San Diego, 
CA) on the HumanOmniExpress array. Subjects were excluded for missingness, heterozygosity, 
chromosomal aberrations, gender check, population outliers, and cryptic relatedness. Genotyping at 
the Z and S alleles was performed in all subjects. Subjects known or found to have alpha-1 
antitrypsin deficiency were excluded. Markers were excluded based on missingness, Hardy-
Weinberg P-values, and low minor allele frequency. Imputation on the COPDGene cohorts was 
performed using MaCH30,31 and minimac37 (version 2012-10-09). Reference panels for the non-
Hispanic whites and African-Americans were the 1000 Genomes29 Phase I v3 European (EUR) and 
cosmopolitan reference panels, respectively. Variants with an r2 value of ≤ 0.3 were removed from 
further analysis.  Logistic regression was performed on pre-bronchodilator spirometry defined 
cases and controls, adjusting for age, sex, pack-years, current smoking, and principal components of 
ancestry, separately in non-Hispanic whites and African-Americans, using PLINK247,48. 
 
Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE; 
SCO104960, NCT00292552, www.eclipse-copd.com): Details of the ECLIPSE study and genome-
wide association analysis have been described previously49. The ECLIPSE study was conducted in 
accordance with the Declaration of Helsinki and good clinical practice guidelines, and was approved 
by the relevant ethics and review boards at the participating centers. All participants provided 
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written informed consent. ECLIPSE was an observational 3-year study of COPD. Both cases and 
controls were aged 40-75 with at least a 10 pack-year smoking history without other respiratory 
diseases; cases were post-bronchodilator GOLD50 Grade 2 and above COPD, and controls had 
normal spirometry (FEV1 > 85% predicted).  Genotyping was performed using the Illumina 
HumanHap 550 V3 (Illumina, San Diego, CA). Subjects and markers with a call rate of < 95% were 
excluded.  Population stratification exclusion and adjustment on self-reported white subjects was 
performed using EIGENSTRAT (EIGENSOFT Version 2.0)51.  Imputation was performed using 
MaCH30,31 and minimac37 (version 2012-10-09) and the 1000 Genomes29 Phase I v3 European (EUR) 
reference panel.  Logistic regression was performed on pre-bronchodilator spirometry defined 
cases and controls, adjusting for age, sex, pack-years, current smoking, and principal components of 
ancestry using PLINK247,48. 
 
Expression Quantitative Trait Loci – Lung (eQTL): The lung eQTL study has been described 
previously23. Briefly, patients who underwent lung surgery were recruited at three academic sites: 
Laval University, University of British Columbia (UBC), and University of Groningen, henceforth 
referred to as Laval, UBC, and Groningen, respectively. Patients from Laval were those undergoing 
lung cancer surgery, the majority of the UBC patients had lung resection for small peripheral lung 
lesions with some samples derived from autopsy or at the time of lung transplantation. At 
Groningen, patients were recruited from those having surgery for various lung diseases, including 
patients that underwent therapeutic resection for lung tumors and lung transplantation. All 
patients provided written informed consent and the study was approved by the ethics committees 
of the Institut universitaire de cardiologie et de pneumologie de Québec and the UBC-Providence 
Health Care Research Institute Ethics Board for Laval and UBC, respectively. The study protocol was 
consistent with the Research Code of the University Medical Center Groningen and Dutch national 
ethical and professional guidelines. COPD diagnosis and severity were determined according to the 
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GOLD50 recommendations. Patients whose lung function could have been influenced by lung 
diseases other than COPD and lung cancer were excluded. This includes patients with alpha-1 
antitrypsin deficiency (n=11), amyloidosis (n=1), bronchiectasis (n=3), bronchiolitis obliterans 
(n=2), bronchopulmonary dysplasia (n=2), cystic fibrosis (n=14), idiopathic pulmonary fibrosis 
(n=13), langerhans cell histiocytosis (n=1), lymphangioleiomyomatosis (n=1), primary pulmonary 
hypertension (n=4), sarcoidosis (n=3) and vascular malformation (n=1).  
 Genotyping was carried out using the Illumina Human1M-Duo BeadChip. Standard 
genotyping quality controls were performed independently in the Laval, UBC and Groningen 
cohorts. Each genotyping set was filtered for low-quality loci with 10th percentile of Illumina 
GenCall score ≤0.1, call rate <97%, Hardy-Weinberg equilibrium P < 1x10-7, and minor allele 
frequency (MAF) <1%. Samples were excluded after consideration for the 10th percentile of 
Illumina GenCall score ≤0.2, genotype completion rate <90%, genotypic and phenotypic gender 
mismatch, unexpected duplicates and genetic relatedness, and genetic background outliers 
detected by STRUCTURE (k=4) with HapMap52 subjects as internal controls. PC1 to PC10 were 
calculated with EIGENSOFT 4.2. Imputation was performed with SHAPEIT53 
(Shapeit.v1.ESHG.linux.x64) and IMPUTE243 (impute_v2.2.2_x86_64_dynamic), and the reference 
set from the 1000 genomes29 project (ALL_1000G_phaselintegrated_v3). Only SNPs that passed the 
cutoff r2 ≥ 0.95 were retained. Single-marker association tests were performed with PLINK 
v1.9047,48 adjusting for age, sex, smoking status, pack-years, ever smoking status, center and PC1 to 
PC10.  
 
Framingham Heart Study (FHS; NCT00005121): Details on pulmonary function in the FHS have 
been previously published54,55. The study was IRB-approved at the relevant institutions and all 
participants provided written informed consent. Data from the most recent exam for each of the 
three generations of families participating in the FHS were analyzed. Genotypes were from the 
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Affymetrix 500K array supplemented by the Affymetrix MIPS 50K.  From a total number of 549,781 
genotyped SNPs, 412,053 were used with the MaCH30,31 program for phasing. A total of 137,728 
genotyped SNPs were removed based on the following filtering criteria: 22,018 SNPs for Hardy-
Weinberg Equilibrium p-value of less than 1x10-6, 48,285 SNPs for a call rate of less than 96.9%, 
66,063 SNPs for a minor allele frequency of less than 0.01, 82 SNPs due to not mapping correctly 
from Build 36 to Build 37 locations, 428 SNPs missing a physical location, 25 SNPs for number of 
Mendelian errors greater than 1000, 786 SNPs due to not being on chromosomes 1-22 or X and 41 
SNPs because they were duplicates. MaCH/minimac30,31,37 were used in this imputation to impute 
the FHS sample using the November 2010 release of the 1000 Genomes29 multi-ethnic panel 
comprised of 1,092 samples. We used GEE implemented in the R package geepack with 
independent correlation matrix and clustering based on family, adjusted for sex, age, smoking 
status, pack years and principal component 1 (to adjust for population stratification). 
 
KARE: Details on the Korean Association Resource project (KARE) have been previously 
published56,57. KARE was initiated in 2007 to undertake genome-wide analyses analysis among 
10,038 participants in the rural-based Ansung and city-based Ansan South Korean cohorts. The 
study was approved at appropriate IRBs from participating institutions and participants provided 
informed consent. KARE3 data were obtained from the third phenotype collection in 2008; lung 
function was collecting using a portable spirometer (Vmax-2130, Sensor Medics, Yorba Linda, CA, 
USA) according to standardized protocols of the American Thoracic Society (ATS). Genotyping was 
performed using the Affymetrix Genome-Wide Human array 5.0 (Affymetrix, Inc., Santa Clara, CA, 
USA). We performed imputation using IMPUTE2 and the 1000 Genomes29 Phase 3 cosmopolitan 
panel.  Markers were converted to genotype from dosage with call rate ≥ 95%, minor allele 
frequency ≥ 1%, p for HWE ≥ 1.0x10-5, imputation quality score ≥ 0.9.  Logistic regression was 
performed using PLINK44. 
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LifeLines: The LifeLines Cohort Study is a large population-based cohort study and biobank that 
was established as a resource for research on complex interactions between environmental, 
phenotypic and genomic factors in the development of chronic diseases and healthy aging58-60. 
Between 2006 and 2013, inhabitants of the northern part of The Netherlands and their families 
were invited to participate, thereby contributing to a three-generation design. Participants visited 
one of the LifeLines research sites for a physical examination, including pre-bronchodilator 
spirometry following ATS guidelines. All participants signed an informed consent form before they 
received an invitation for the physical examination. The LifeLines Cohort Study is conducted 
according to the principles of the Declaration of Helsinki and in accordance with research code 
University Medical Center Groningen (UMCG), The Netherlands. The LifeLines study is approved by 
the medical ethical committee of the UMCG. 
 Blood samples for a subset of individuals were genotyped using the Illumina CytoSNP-12v2 
array. Independent Caucasian-ancestry samples (n = 13,436) have been imputed using the 1000 
Genomes29 phase1 v3 reference panels. Quality control of the data is based on SNP filtering on MAF 
above 0.001, HWE p-value > 1x10-4, call rate of 0.95 using PLINK41, and PCA to check for population 
outliers resulting in 268,407 SNPs and 13,436 samples kept for genome-wide association analysis. 
Before imputation, the genotypes were pre-phased using SHAPEIT242 and aligned to the reference 
panels using Genotype Harmonizer (www.molgenis.org/systemsgenetics) in order to resolve 
strand issues. The samples were imputed using minimac37 (version 2012-10-09), yielding 
28,681,763 SNPs.   Associations between genomic dosages with moderate/severe COPD were 
assessed with logistic regression models adjusted for age, smoking status (never/ever), current 
smoking (no/yes), pack years smoked and sex. All analysis were performed in software package 
PLINK version 1.0741,44.  
 
 
 
77 
Lovelace: The LSC has been actively enrolling smokers from the Albuquerque, NM metropolitan 
area since 2001 and has been previously decribed61. All participants provided written informed 
consent and the study was approved by the relevant IRB. Longitudinal studies to predict lung 
cancer and other chronic pulmonary diseases are conducted through assessing biomarkers present 
in sputum, blood, and urine samples. Enrollment was restricted to current and former smokers age 
40 to 74 y with a minimum of 10 pack-years of smoking and no personal history of lung cancer. A 
detailed questionnaire written in English was used to collect information on demographics, 
medical, cigarette smoking, and exposure history, socioeconomic status, diet, and quality of life. 
Sputum samples were collected by induction and stored in Saccomanno's fixative. Pulmonary 
function testing was performed at each visit. All participants signed a consent form, and the 
Western Institutional Review Board approved this project. The GWAS discovery set was comprised 
of 1200 Caucasian (self-reported) smokers with methylation status of 12 tumor suppressor genes 
measured in sputum DNA samples. 
The HumanOmni2.5-4v1-H BeadChip (Illumina, San Diego, CA) was used to genotype 2,450,000 
SNPs in 1200 Caucasian smokers from the LSC. We removed 37 subjects due to low call rate (< 
95%, n = 7), low heterozygosity (n = 1), low Caucasian ancestry (< 85%, n = 2) and high relatedness 
with other samples (n = 27). Furthermore, SNPs were excluded if they had a call rate of < 90%, a 
minor allele frequency (MAF) < 0.008, or P < 10-8 for Hardy-Weinberg equilibrium test, or were on 
Y or pseudo-autosomal region of X. The MAF cutoff is a technical one to identify at least 20 
heterozygotes for accurate genotype clustering required by GenomeStudio. After quality 
assessment, 1163 subjects with 1,599,980 SNPs remained in the genetic association analysis.  
Logistic regression was performed using PLINK. 
 
Multi-Ethnic Study of Atherosclerosis (MESA): MESA is a longitudinal study of subclinical 
cardiovascular disease and risk factors that predict progression to clinically overt cardiovascular 
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disease or progression of the subclinical disease62. Between 2000 and 2002, MESA recruited 6,814 
men and women 45 to 84 years of age from Forsyth County, North Carolina; New York City; 
Baltimore; St. Paul, Minnesota; Chicago; and Los Angeles. Exclusion criteria were clinical 
cardiovascular disease, weight exceeding 136 kg (300 lb.), pregnancy, and impediment to long-term 
participation. The MESA Family Study recruited 1,595 African American and Hispanic participants, 
generally siblings of MESA participants, using the same inclusion and exclusion criteria as MESA 
except that clinical cardiovascular disease was permitted. The MESA Air Pollution Study recruited 
an additional 257 participants from Los Angeles and Riverside County, CA, and Rockland County, 
NY, using the same criteria as MESA, except that participants were ages 50 to 89 who lived in the 
area more than 50% of the year and had no plans to move in the next five years63. The MESA Lung 
Study performed spirometry following the 2005 ATS/ERS guidelines in a subset of the MESA and 
MESA Family Studies and all of the new recruits in the MESA Air Pollution Study, as previously 
described64. All participants provided informed consent and the protocols of MESA were approved 
by the IRBs of collaborating institutions and the National Heart, Lung and Blood Institute. 
 Participants in the original MESA cohort, the MESA Family Study and the MESA Air Pollution 
Study who consented to genetic analyses were genotyped in 2009 using the Affymetrix Human SNP 
array 6.0. Genotype quality control for these data included filter on SNP level call rate < 95%, 
individual level call rate < 95%, heterozygosity > 53%, described previously65. The cleaned 
genotypic data was deposited with MESA phenotypic data into dbGaP as the MESA SHARe project 
(study accession phs000209); 8,224 consenting individuals (2,685 White, 2,588 non-Hispanic 
African-American, 2,174 Hispanic, 777 Chinese) were included, with 897,981 SNPs passing study 
specific quality control (QC). For GWAS, IMPUTE version 2.2.2 was used to perform imputation for 
the MESA SHARe participants using the cosmopolitan 1,000 Genomes29 Phase 1 v3 March 2012 
reference set.  Logistic regression was performed using SNPTEST v2.4.066. 
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National Emphysema Treatment Trial (NETT; NCT00000606, 
www.nhlbi.nih.gov/health/prof/lung/nett/) and Normative Aging Study (NAS): Details of the 
National Emphysema Treatment Trial have been described previously67. NETT was a multicenter 
clinical trial to evaluate lung volume reduction surgery. All participants provided written informed 
consent and the study was approved by the IRB at all participating institutions. Enrolled subjects 
had severe airflow obstruction by post-bronchodilator spirometry (FEV1 < 45% predicted) and 
evidence of emphysema on computed tomography (CT) chest imaging; exclusion criteria included 
significant sputum production or bronchiectasis. A subset of 382 self-reported white subjects 
without severe alpha-1 antitrypsin deficiency were enrolled in the NETT Genetics Ancillary Study.    
 The Normative Aging Study is a longitudinal study of healthy men established in 1963 and 
conducted by the Veterans Administration (VA)68. Participants provided written informed consent 
at each visit, and the VA Boston Healthcare System Institutional Review Board approved the study. 
Men aged 21 to 80 years from the greater Boston area, free of known chronic medical conditions, 
were enrolled. Smoking controls were of self-reported white ancestry and at least 10 pack-years of 
cigarette smoking with no evidence of airflow obstruction on spirometry on their most recent visit. 
Genotyping for NETT-NAS was performed using the Illumina Quad 610 array (Illumina, San Diego, 
CA), with quality control, population stratification adjustment, as described previously69,70. 
Imputation was performed using MaCH30,31 and minimac37 (version 2012-10-09) and the 1000 
Genomes Phase I v3 European (EUR) reference panel. Logistic regression was performed on pre-
bronchodilator spirometry defined cases and controls, adjusting for age, sex, pack-years, current 
smoking, and principal components of ancestry using PLINK247,48. 
 
 
GenKOLS (Norway): Details on the Norwegian GenKOLS (Genetics of Chronic Obstructive Lung 
Disease, GSK code RES11080) study have been described previously71. Subjects with > 2.5 pack 
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years of smoking history were recruited from Bergen, Norway; cases had post-bronchodilator 
GOLD 2 or greater disease50, while controls had normal spirometry; subjects with severe alpha-1 
antitrypsin deficiency and other lung diseases (aside from asthma) were excluded. The study was 
performed in accordance with the ethical standards laid down in the Helsinki Declaration. The 
Regional Committee for Medical Research Ethics (REK Vest), the Norwegian Data Inspectorate and 
the Norwegian Department of Health approved the case–control study. A written informed consent 
was obtained from all participants. Genotyping was performed using Illumina HumanHap 550 
arrays (Illumina, San Diego, CA), with quality control, population stratification adjustment as 
previously described. Imputation was performed using MaCH30,31 and minimac37 (version 2012-10-
09) and the 1000 Genomes29 Phase I v3 European (EUR) reference panel.  Logistic regression was 
performed on pre-bronchodilator spirometry defined cases and controls, adjusting for age, sex, 
pack-years, current smoking, and principal components of ancestry using PLINK247,48. 
 
The Rotterdam Study: The Rotterdam Study is a prospective population-based cohort study 
founded in 1990 in a suburb of Rotterdam, the Netherlands72,73. The first cohort (RS-I) consists of 
7,983 participants, aged 55 years and over. The second cohort (RS-II) was recruited in 2000 with 
the same inclusion criteria. The third cohort (RS-III) consists of 3,932 participants, aged 45 years 
and over and was recruited in 2006. The Rotterdam Study was approved by the institutional review 
board (Medical Ethics Committee) of the Erasmus Medical Center and by the review board of The 
Netherlands Ministry of Health, Welfare and Sports. All participants provided written informed 
consent. Spirometry was performed by trained paramedical personnel using the Master Screen® 
PFT Pro (CareFusion, San Diego, CA) according to the American Thoracic Society(ATS)/European 
Respiratory Society (ERS) guidelines. 
 A total of 6,318 subjects were genotyped in RS I, 2,516 in RS II and 3,540 subjects in RS III. 
Exclusions included a call rate < 98%, Hardy-Weinberg P < 1x10-6 and MAF < 0.01%. A total of 
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6,291 for RS I, 2,157 for RS II and 3,048 for RS III passed genotyping quality control. Regression 
coefficients and their standard errors were determined using the ProbABEL 32 program according 
to an additive model. 
 
Subpopulations and intermediate outcome measures in COPD study (SPIROMICS; 
NCT01969344): Participants of the NHLBI SPIROMICS study were 40-80 years of age at baseline 
with a smoking history ≥20 pack-years. Recruitment included non-smokers, smokers without 
COPD, mild-moderate COPD, and severe COPD74. All participants provided written informed 
consent and the Institutional Review Boards/Ethics Committees of all the cooperating institutions 
approved the study protocols. All SPIROMICS study participants have been comprehensively 
characterized with standardized comprehensive questionnaires (including clinical outcomes such 
as exacerbations requiring healthcare utilization, medication use, St. George’s Respiratory 
Questionnaire [SGRQ], and BODE index), pre- and post-bronchodilator lung function, and CT scan 
imaging. Genome wide genotyping was performed using the Illumina OmniExpress HumanExome 
BeadChip using standard techniques in the first 571 subjects with COPD and 175 controls.  
Imputation was performed against 1000 Genomes reference panels using Impute-v2.30 using a 
quality cutoff of 0.9, and association analysis performed using PLINK. 
 
Studies with Custom Genotyping: 
Boston Early-Onset COPD Study (BEOCOPD; ClinicalTrials.gov: NCT01177618): Details of the 
BECOPD study have been described previously75,76. IRB approval was obtained for the study and all 
participants provided written informed consent. BEOCOPD is an an extended pedigree study 
constructed based on probands under 53 years of age with severe COPD (defined as forced 
expiratory volume in one second (FEV1) < 40% predicted) and without severe alpha-1 antitrypsin 
deficiency.  Given the small number of non-white subjects in this cohort, only white subjects were 
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included in this analysis.  Extended pedigrees from BEOCOPD, ICGN, TCGS-Poland, and TCGS-Korea 
were genotyped together on the Illumina HumanExome v1.2 array with custom content (see 
below).  Subject quality control included kinship via KING77 and kinship278, genotyping success rate, 
sex check, homozygosity, Mendelian errors.  Markers were assessed for missingness, concordance 
between duplicate samples, and Hardy-Weinberg equilibrium. Assessment for population outliers 
and control for population stratification was performed using TRACE v1.079,80 and HapMap 
population 52 as the reference. Single-variant association analysis for pre-bronchodilator moderate-
to-severe COPD, adjusting for age, pack-years, sex, and current and ever smoking, was performed in 
EOCOPD and ICGN together using a covariate additionally indicating study, via a logistic mixed 
model as implemented in GMMAT version 0.5 in R (version 3.2.0, http://www.R-project.org/)81. 
 
International COPD Genetics Network (ICGN): The ICGN has been described previously82,83. ICGN 
recruited subjects (FEV1 < 60% predicted and FEV1/FVC < 90% predicted between ages 45-65) as 
probands and then enrolled available siblings and parents of the proband. The study was IRB 
approved at all relevant institutions and participants provided written informed consent. Given the 
small number of non-white subjects in this cohort, only white subjects were included in this 
analysis. Genotyping and analysis was performed as detailed above (in the BEOCOPD section). 
 
Transcontinental COPD Genetics Study (TCGS) – Korea and Poland: TCGS has been described 
previously84 and was comprised of two case-control studies, based in Poland and in Korea. The 
study was approved by the appropriate IRBs and all participants provided written informed 
consent. Both studies recruited individuals between 40 and 80 years of age, with at least 10 pack-
years of cigarette smoking; where cases had severe COPD (FEV1 < 50% predicted) and controls had 
normal spirometry. Subjects with other lung disease were excluded. TCGS-Poland enrolled white 
individuals, and TCGS-Korea enrolled Korean individuals.  Details of genotyping are described 
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above (in the BEOCOPD section).  We used PLINK247,48 to perform logistic regression, adjusting for 
age, pack-years, sex, and current smoking status. 
 
UK BiLEVE Cohort Information:  UK BiLEVE is a subset of UK Biobank and is described in detail 
elsewhere85. In brief, UK Biobank comprised 502,682 individuals of which 472,858 were of self-
reported European ancestry and 275,939 had at least two measures of FEV1 and FVC and passed 
ATS/ERS quality criteria86. Spirometry data was obtained using a Vitalograph Pneumotrac 6800 
(Buckingham, UK); at least two measures were obtained. From these 275,939 individuals, 50,000 
individuals were selected based on % predicted FEV1 such that 10,000 individuals with low FEV1, 
10,000 individuals with near-average FEV1, and 5,000 with high FEV1 were selected from amongst 
never smokers (total n=105,272) and the same numbers from amongst the heavy smokers (total 
n=46,758). Equal numbers of males and females were selected and the number of individuals 
selected within each age-sex band was proportional to the number of individuals available for 
sampling for each band. Genotyping was undertaken using the Affymetrix Axiom UK BiLEVE array85 
and imputed to the 1000 Genomes Project29 Phase 1 and UK10K87 combined panel. Of the 50,008 
samples selected, 48,943 unrelated individuals passed all genotype and sample quality control 
steps and were used as the sampling frame for selection of samples included in the analysis 
described here. The UK Biobank received ethics approval from the National Health Service National 
Research Ethics Service (Ref 11/NW/0382). All participants provided written informed consent. 
 In UK BiLEVE, COPD status was defined based on spirometry with individuals with % 
predicted FEV1<80% and FEV1/FVC<0.7 (indicative of COPD GOLD stage 2 or worse) selected as 
COPD cases. COPD controls were individuals that did not meet the case criteria and were selected 
from the high % predicted FEV1 group only (all had % predicted FEV1>80%). Analyses were carried 
out using the score test, implemented in SNPTEST v2.5b4 and assuming an additive genetic model 
of genotype dose. For never smokers, sex, age and the first 10 ancestry principal components were 
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included as covariates. For heavy smokers, current smoking status and pack years were included as 
additional covariates.   
 
 
85 
Additional Supplemental Methods 
Fine Mapping Analysis Methods 
 We also attempted to determine, at each locus, whether we could identify a potentially 
causal variant.  We performed these analyses using European ancestry subjects with genome-wide 
data, and excluded variants that were not present in at least 80% of the full sample.  We used a +/- 
250kb region around the top variant in each locus, and used two methods. We calculated 
approximate Bayes factors using the method of Wakefield88, and determined the 95% credible set.  
While trans-ethnic mapping can significantly assist in fine-mapping, the number of non-European 
samples in our study was too low to leverage either PAINTOR289 or MANTRA90.  
Functional Enrichment Analysis Methods 
 To identify enriched cell types for our COPD associations, we applied LD score regression to 
GenoSkyline91 lung tissue annotations (the default LD score regression annotations collapse lung 
into the cardiovascular tissue type), as well as cell-type specific annotations from LD score 
regression92. We also performed analysis using only the 22 genome-wide significant loci and tested 
for enrichment of imputed chromatin marks from ROADMAP3. Further, we applied a more 
sophisticated analysis adjusting for local linkage disequilibrium patterns, GoShifter93, Finally, we 
examined overlap with gene expression datasets using SNPsea94.  
Quantitative Imaging Overlap Analysis Methods 
 To explore the relationship between our top COPD-associated variants and imaging features 
of emphysema and airway thickness, we queried data from a GWAS of COPD quantitative imaging 
features27. For each genome-wide significant COPD susceptibility locus in our overall meta-analysis, 
we assessed the corresponding quantitative imaging GWAS effect size, effect direction, and P value 
for association with the following quantitative imaging traits: %LAA-950 (percentage low 
attenuation area, using a threshold of -950 Hounsfield units); Perc15 (value of Hounsfield units at 
the 15th percentile of the density histogram); Pi10 (airway wall area: the value for a hypothetical 
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10-mm airway obtained by plotting a regression line of the square root of the airway wall area 
versus the airway internal perimeter); and WAP (percentage of the wall area compared to the total 
bronchial area). 
Gene Set Enrichment Analysis Methods 
 As an attempt to minimize false positives in our gene set enrichment analysis, we divided 
the Stage 1 GWAS cohorts with full genome-wide data into two sets of roughly equal size. We then 
used i-GSEA4GWAS (http://gsea4gwas.psych.ac.cn/)95 for each of the two GWAS data sets to assess 
enrichment of COPD GWAS loci in BioCarta (http://cgap.nci.nih.gov/Pathways/BioCarta_Pathways) 
and KEGG96 pathways as well as gene ontology (GO) terms97,98. We first evaluated GO terms and 
pathways with a false-discovery rate (FDR) less than 5% in both analysis sets and then used a more 
stringent threshold of FDR < 1% to evaluate overlap of GO term and pathway enrichment in our 
two analysis sets. 
Causal Gene Analysis Methods 
 For the genome-wide significant loci from the overall meta-analysis, we explored potential 
causative genes at each association locus using the PrixFixe method99, assuming co-function of all 
significant loci. As required by the PrixFixe method, we assured our genome-wide significant loci 
were present in dbSNP v137100 and were represented HapMap52 phase III data; for loci not meeting 
these requirements, proxy SNPs from HapMap phase III were selected based on strongest LD (r2) 
with index SNP (see Supplemental Table S15 for details of the proxy variant used at each genome-
wide significant locus).  
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Supplemental Results: 
Fine Mapping Analysis Results 
 We examined our top 22 GWAS loci from the overall meta-analysis to examine the size of 
the 95% credible set at each locus. We found that the association signals for these 22 loci were 
minimal in the African-Americans (our largest non-European ethnicity), likely due to inadequate 
power. At 12 loci with some evidence of association (P < 0.001) in individuals of African ancestry, 
we determined the linkage disequilibrium between top variants in African Americans (AA) and the 
top overall variants at these loci. Results of these fine mapping analyses are presented in Table S20.  
In the European only fine-mapping analysis, for 3 of the loci, the 95% credible set had < 10 variants, 
with an additional 2 with < 20. For two loci (SFPTD and CFDP1), we found variants in the African-
Americans that were in modest LD (arbitrarily set at r2 > 0.3 or D’ > 0.4) that were in the 95% 
credible set.  Overall, these results suggest some loci for which a reasonable number of variants can 
be tested, and others for which functional annotation, sample size, and studies of other ethnicities 
could be most useful. 
Lung eQTL Analysis Results 
 Genotypes and gene expression was available for 409 patients from Laval, 287 patients 
from the UBC, and 342 patients from Groningen. One hundred ten eQTL at 20 loci were nominally 
(P < 0.05) significant in the meta-analysis; 14 eQTL (P value < 5.2 x 10-8) involving 6 loci reached 
significance after Bonferroni correction. Supplemental Table S6 shows the most significant gene-
SNP pairs at each locus. rs17486278 on chromosome 15 was also significantly associated with 
CHRNA5 and PSMA4 as previously reported101.   
Functional Enrichment Analysis Results 
 The LD score regression functional enrichment analysis identified lung as the primary 
tissue (coefficient Z-score, 2.54), and fetal lung H3K4me1 as the primary cell type (Z-score, 4.4).   
No inflammatory cell types were nominally significant (Z all < 1.75).  In the ROADMAP3 chromatin 
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marks analysis, no individual cell was significant after correction for multiple testing, though we 
identified nominal significance (P value, using GWAS background < 0.05) for A549 lung cancer, 
NHLF lung fibroblast, and primary helper and effector T cells from peripheral blood (0.01 < P < 
0.05); top ranked associations were fetal intestine, thymus, and rectal mucosa.  Using GoShifter93 
we identified nominal significance for fetal lung and IMR90 lung fibroblasts (P = 0.006 and 0.049 
respectively); there was no evidence for immune cell enrichment.   
With the SNPsea94 analysis, lung related cells ranked in the top annotations in both the 
Affymetrix (Lung, Trachea, Bronchial epithelial cells with unadjusted 0.02 < P < 0.03) and 
FANTOM5 (lung, mesothelioma, and alveolar cell carcinoma 0.001 < P < 0.03).  In the Immgen 
dataset, our top enrichment was for lung dendritic cells (P = 0.002).  No enrichment was seen for 
neutrophils, T-cells, and lung macrophages (P all > 0.09).   
In summary, multiple analyses identified enrichment of lung cell types; in contrast, we 
failed to find convincing evidence of enrichment for other cell types, including inflammatory cells.  
While this lack of enrichment could reflect a limited influence of genetically driven inflammatory 
factors contributing to COPD, this could also represent limitations in the power and assessment 
appropriate cell types in these datasets. 
Quantitative Imaging Overlap Analysis Results 
 We evaluated our 22 COPD susceptibility loci in a GWAS of COPD-related quantitative 
imaging phenotypes27 to assess differential effects of our COPD susceptibility loci on emphysema 
and airway imaging phenotypes (Supplemental Table S14). 
Gene Set Enrichment Analysis Results 
To assess enrichment of our Stage 1 association analysis results in biologic pathways, we 
divided the Stage 1 analysis cohorts into discovery and validation sets of roughly equal size and 
analyzed each set using i-GSEA4GWAS (http://gsea4gwas.psych.ac.cn/)95. We identified 32 GO 
terms and canonical pathways with significant enrichment (false discovery rate (FDR) < 5%) in 
 
 
89 
both sets. These enriched pathways related to cell homeostasis, cell differentiation, lymphoid organ 
and immune system development, biopeptide signaling and transcription factor complex activity. 
Using a more stringent FDR threshold of <1%, five pathways and GO terms overlapped between the 
discovery and validation analysis sets, including the T cell receptor pathway, sugar metabolism, ion 
and substrate channel activities, and response to organic substance stimulus. 
Causal Gene Analysis Results 
 We used the PrixFixe method99 to rank potential causal genes based on mutual function 
across all COPD genome-wide loci (Supplemental Table S16). In regions such as chr15q25.1, chr 
16p11.2, chr16q23.1, and chr19q13.2 with multiple genes in an LD window with our top COPD 
variant, the PrixFixe method did not rank the closest gene as the most likely causative gene based 
on mutual function of genes at all top COPD loci. 
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